Article
Nascent RNA antagonizes the interaction of a set of
regulatory proteins with chromatin
Graphical abstract
Authors
Lenka Skalska, Victoria Begley,
Manuel Beltran, ...,
Ambrosius P. Snijders, Till Bartke,
Richard G. Jenner
Correspondence
r.jenner@ucl.ac.uk
In brief
Nascent RNA interacts with a wide array
of regulatory proteins but its impact on
chromatin composition has not been
assessed. Skalska and colleagues use
proteomics methods to reveal that
nascent RNA antagonizes the association
of a set of regulatory proteins with
chromatin.
Highlights
d
Pol II inhibition induced recruitment of a set of regulatory
proteins to chromatin
d
Many of these changes were also observed upon RNA
degradation
d
RNA binds a set of chromatin modifiers and inhibits
interaction with nucleosomes
d
P-TEFb binds pre-mRNA, and 7SK regulates its interaction
with RNA and chromatin
Skalska et al., 2021, Molecular Cell 81, 1–16
July 15, 2021 ª 2021 Elsevier Inc.
https://doi.org/10.1016/j.molcel.2021.05.026
ll
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
Nascent RNA antagonizes the interaction
of a set of regulatory proteins with chromatin
Lenka Skalska,1,6,7 Victoria Begley,1,6 Manuel Beltran,1,6,8 Saulius Lukauskas,2 Garima Khandelwal,1 Peter Faull,3,9
Amandeep Bhamra,5 Manuel Tavares,1 Rachel Wellman,1 Andrey Tvardovskiy,2 Benjamin M. Foster,2,10
Igor Ruiz de los Mozos,3,4 Javier Herrero,1 Silvia Surinova,5 Ambrosius P. Snijders,3 Till Bartke,2
and Richard G. Jenner1,11,*
1UCL
Cancer Institute and Cancer Research UK UCL Centre, University College London (UCL), London WC1E 6BT, UK
€nchen, Neuherberg 85764, Germany
of Functional Epigenetics, Helmholtz Zentrum Mu
3The Francis Crick Institute, London NW1 1AT, UK
4Institute of Neurology, UCL, London WC1N 3BG, UK
5Proteomics Research Translational Technology Platform, UCL Cancer Institute and Cancer Research UK UCL Centre, University College
London (UCL), London WC1E 6BT, UK
6These authors contributed equally
7Present address: Barking, Havering, and Redbridge University Hospitals NHS Trust, Romford, UK
8Present address: Department of Biology and Biotechnology Charles Darwin, Sapienza University of Rome, Rome, Italy
9Present address: College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA
10Present address: Department of Biochemistry, University of Oxford, Oxford, UK
11Lead contact
*Correspondence: r.jenner@ucl.ac.uk
https://doi.org/10.1016/j.molcel.2021.05.026
2Institute
SUMMARY
A number of regulatory factors are recruited to chromatin by specialized RNAs. Whether RNA has a more general role in regulating the interaction of proteins with chromatin has not been determined. We used proteomics methods to measure the global impact of nascent RNA on chromatin in embryonic stem cells. Surprisingly, we found that nascent RNA primarily antagonized the interaction of chromatin modifiers and
transcriptional regulators with chromatin. Transcriptional inhibition and RNA degradation induced recruitment of a set of transcriptional regulators, chromatin modifiers, nucleosome remodelers, and regulators of
higher-order structure. RNA directly bound to factors, including BAF, NuRD, EHMT1, and INO80 and inhibited
their interaction with nucleosomes. The transcriptional elongation factor P-TEFb directly bound pre-mRNA,
and its recruitment to chromatin upon Pol II inhibition was regulated by the 7SK ribonucleoprotein complex.
We postulate that by antagonizing the interaction of regulatory proteins with chromatin, nascent RNA links
transcriptional output with chromatin composition.
INTRODUCTION
It is well established that the transcription of DNA into coding and
non-coding RNAs (ncRNAs) is regulated by proteins that
respond to DNA sequence composition and chromatin state. It
is also becoming clear that RNA molecules can themselves
play a role in transcriptional and chromatin regulation. This was
first demonstrated in mammalian cells for the transactivation
response element (TAR), an RNA stem-loop formed at the
50 end of nascent HIV transcripts, and for the cellular ncRNA,
7SK. TAR binds the HIV transactivator protein Tat, and these factors act together to release the positive transcription elongation
factor b (P-TEFb) from the inhibitory 7SK ribonucleoprotein
(RNP) complex to activate HIV transcriptional elongation
(Barboric et al., 2007; Garber et al., 1998; Michels et al., 2003;
Sedore et al., 2007; Wei et al., 1998; Yik et al., 2003). Since
then, a number of long non-coding RNAs (lncRNAs) and
enhancer RNAs (eRNAs) have been found to interact with tran-
scriptional and chromatin regulatory proteins and modulate their
recruitment or activity at specific sites on chromatin (Rinn and
Chang, 2012).
In addition to the functions of specialized ncRNAs, RNA also
acts in a global manner to regulate chromatin state. RNA and
transcription affect higher-order structure across the genome
(Barutcu et al., 2019; Heinz et al., 2018; Li et al., 2015; Saldaña-Meyer et al., 2019). Building on models in which RNA
forms a static nuclear matrix (Nickerson et al., 1989), it was
more recently proposed that pre-mRNAs and other nascent
transcripts form a dynamic nuclear RNA matrix that holds
open active chromatin (Nozawa et al., 2017). Consistent with
a more general role for RNA in chromatin regulation, recent
studies demonstrate that chromatin regulators interact with a
wide array of nascent transcripts. Although first identified to
bind specific ncRNAs, polycomb repressive complex 2
(PRC2), DNMT1 and DNMT3A, LSD1/KDM1A, CBX3, YY1,
HDAC1, and CHD4 primarily interact with nascent pre-mRNAs
Molecular Cell 81, 1–16, July 15, 2021 ª 2021 Elsevier Inc. 1
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
A
B
C
D
E
(legend on next page)
2 Molecular Cell 81, 1–16, July 15, 2021
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
(Beltran et al., 2016; Hendrickson et al., 2016; Kaneko et al.,
2013; Savell et al., 2016; Sigova et al., 2015). Similarly, unbiased screens for proteins interacting with nascent RNA or
non-polyadenylated transcripts in cells have revealed enrichment for chromatin regulators (Bao et al., 2018; He et al.,
2016; Trendel et al., 2019).
For the majority of factors identified to bind RNA in cells, the
effect on their association with chromatin has not been determined. Although RNAs have primarily been considered to recruit regulatory proteins to chromatin, it has become apparent
that nascent RNA can antagonize the association of proteins
with chromatin. This is best understood for the repressive chromatin modifier PRC2. PRC2 directly interacts with pre-mRNAs
at essentially all active genes (Beltran et al., 2016; Davidovich
et al., 2013; Kaneko et al., 2013) but preferentially binds Gquadruplex (G4)-forming sequences within these transcripts
(Beltran et al., 2019; Kaneko et al., 2014; Wang et al., 2017a).
In vitro, RNA competes with nucleosomes for PRC2 binding
and inhibits PRC2 catalytic activity (Beltran et al., 2016, 2019;
Cifuentes-Rojas et al., 2014; Herzog et al., 2014; Kaneko
et al., 2014; Wang et al., 2017b; Zhang et al., 2019). In cells,
blocking RNA polymerase II (RNA Pol II) transcription (Hosogane et al., 2016; Kaneko et al., 2014; Riising et al., 2014) or degrading RNA (Beltran et al., 2016) triggers PRC2 recruitment to
active genes. Reciprocally, blocking nuclear RNA degradation
(Garland et al., 2019) or tethering G4-forming RNAs to
repressed genes (Beltran et al., 2019) removes PRC2 from
chromatin. Thus, pre-mRNA regulates its own production by
preventing the recruitment of PRC2 to chromatin at active
genes (Skalska et al., 2017). However, the broader impact of
nascent RNA on the interaction of proteins with chromatin
has not been determined.
We used proteomics methods to determine the effect of
nascent RNA on the interaction of proteins with chromatin in embryonic stem cells (ESCs). Unexpectedly, we found that nascent
RNA primarily acted to inhibit the interaction of chromatin and
transcriptional regulatory proteins with chromatin. We further
demonstrate that nascent pre-mRNA directly binds to P-TEFb
and that the 7SK RNP regulates the interaction of P-TEFb with
nascent RNA and chromatin.
RESULTS
A set of regulatory proteins are recruited to chromatin
upon transcriptional inhibition
We sought to determine the impact of RNA Pol II transcription of
nascent RNA on the association of proteins with chromatin using
a stable isotope labeling with amino acids in cell culture (SILAC)based quantitative proteomics approach. Mouse ESCs were
treated with the transcription factor II human (TFIIH) inhibitor triptolide, which blocks transcriptional initiation and leads to RNA
Pol II degradation, or the CDK9 inhibitor flavopiridol, which
blocks transcriptional elongation, for 3 or 9 h (Figures 1A and
S1A). These time points were chosen due to the previous observation that PRC2 was recruited to chromatin in ESC after 9 h of
treatment with triptolide (Riising et al., 2014). RNA sequencing
(RNA-seq) revealed that flavopiridol and triptolide treatments
had a greater effect on chromatin-associated nascent RNA
(rRNA-depleted intronic reads) than on mature polyA+ exonic
RNA and that transcription had largely ceased by 9 h (Figures
S1B and S1C). Chromatin fractions were purified and verified
by silver stain and immunoblotting (Figures S1D and S1E). The
constituent proteins were then quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) relative to chromatin from DMSO-treated cells at the same time point.
This analysis revealed a set of proteins lost from chromatin
upon RNA Pol II inhibition and, unexpectedly, a set of proteins recruited to chromatin upon RNA Pol II inhibition (Figure 1B; Table
S1). These changes were observed upon treatment with both flavopiridol and triptolide (r = 0.66, p = 2.9 3 10196, Pearson correlation and t test), and similar changes were evident at 3 and 9 h for
both flavopiridol (r = 0.53, p = 8 3 10108) and triptolide (r = 0.62,
p = 4.3 3 10162) (Figure S1F). The changes were not due to the
indirect effects of transcriptional inhibition on the cell cycle; treatment with flavopiridol and triptolide had similar effects on chromatin but opposite effects on the relative proportions of cells in
G1 versus M phase (Figure S1G). Similarly, RNA Pol II inhibition
had little effect on apoptosis (Figure S1H) or DNA damage
signaling (gH2A.X; Figure S1I), especially at the 3-h time point.
Similar effects could be observed after a 1-h treatment with flavopiridol and with a lower drug concentration (Figure S1J), again,
Figure 1. A set of regulatory proteins are recruited to chromatin upon transcriptional inhibition
(A) Experimental strategy. ESCs were treated with DMSO, flavopiridol, or triptolide for 3 or 9 h, the chromatin fractions purified, and proteins quantified relative to
DMSO by SILAC.
(B) Significance (q value/FDR) of changes in the association of proteins with chromatin upon treatment with flavopiridol (left) or triptolide (right) versus DMSO at
9 h. The GO term RNA processing (blue) was significantly enriched (p = 8.9 3 1052, hypergeometric) in the set of proteins depleted from chromatin (FDR < 0.05) in
both treatments. The GO term Chromatin Organization (red) was significantly enriched (p = 4 3 105) in the set of proteins recruited to chromatin (FDR < 0.05).
Proteins with these functions are highlighted and their frequencies within the sets of proteins recruited or depleted from chromatin shown above.
(C) Proteins that exhibited significantly increased abundance in the chromatin fraction upon RNA Pol II inhibition with flavopiridol and triptolide (9 h). Protein
complexes are labeled if a significant proportion of their subunits were increased on chromatin (p < 0.05, hypergeometric). Interactions between proteins
(STRING) are shown as lines. Changes in the chromatin association of individual proteins upon treatment with flavopiridol are indicated by color, according to the
scale on the right, and by the outline (black FDR < 0.05, white FDR > 0.05).
(D) Immunoblots for proteins representative of those shown in (C) in the cytoplasmic, nucleoplasmic, and chromatin fractions and whole-cell extract (WCE) taken
from ESCs after 0, 3, or 6 h of incubation with flavopiridol.
(E) Top, strategy: after the 3-h incubation, flavopiridol was washed out, cells incubated for a further 3 h, and then harvested. Bottom: proteins either recruited to or
depleted from chromatin (FDR < 0.05) upon treatment with flavopiridol at the 3-h time point (n = 519) ordered by the change in chromatin binding (average of
3- and 9-h time points). Changes in chromatin association induced by flavopiridol washout (relative to 3-h flavopiridol) are shown below and are anti-correlated
with the changes initially induced by flavopiridol (r = 0.34, 8.5 3 1016, n = 519). Changes in chromatin association are colored according to the scale beneath.
See also Figure S1 and Tables S1 and S2.
Molecular Cell 81, 1–16, July 15, 2021 3
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
A
B
C
D
E
Figure 2. RNA degradation has similar effects to RNA Pol II inhibition on the interaction of proteins with chromatin
(A) Experimental strategy. ESCs were permeabilized, mock-treated or treated with RNaseA to degrade RNA, chromatin fractions purified, and proteins quantified
by label-free LC-MS/MS.
(B) Significance of changes in the association of proteins with chromatin upon RNaseA treatment versus mock-treated control. Proteins with functions in RNA
processing and chromatin organization are highlighted in blue or red, respectively, and their frequencies in the sets of proteins recruited or depleted from
chromatin (FDR < 0.05) shown above.
(legend continued on next page)
4 Molecular Cell 81, 1–16, July 15, 2021
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
consistent with changes being a direct effect of transcriptional
inhibition.
We examined the set of proteins significantly depleted (false
discovery rate [FDR] < 0.05) from chromatin upon RNA Pol II inhibition with both flavopiridol and with triptolide (9 h; n = 241). As
may be expected, this revealed enrichment of proteins with functions in RNA processing (Gene Ontology [GO]: 0006396; p =
8.9 3 1052, hypergeometric), including significant enrichment
of subunits of the spliceosome, exosome, polyA complex,
exon junction complex, and RNA Pol II-bound factors such as
the PAF complex and SPT6/ISW1 (Figures 1B and S1K; Table
S2). These proteins also included HNRNPU, previously shown
to interact with chromatin in an RNA-dependent manner (Nozawa et al., 2017). Thus, these factors act as positive controls
and suggest that the observed changes are caused by the loss
of RNA Pol II transcription.
We then turned our attention to the set of proteins recruited to
chromatin upon RNA Pol II inhibition with both flavopiridol and
triptolide (n = 281). We found an enrichment of factors with roles
in chromatin organization (GO: 0006325; p = 4 3 105), gene
expression (Reactome [REAC]: R-MMU-74160; p = 6 3 104),
and ESC pluripotency (WP: PluriNetWork; p = 5 3 1012) (Figures
1B and S1K; Table S2). A number of complexes exhibited a significant enrichment of subunits (p < 0.05, hypergeometric) in the
set of proteins recruited to chromatin upon RNA Pol II inhibition
(Figure 1C; Table S2). These included PRC2, which has previously been shown to be recruited to chromatin upon transcriptional inhibition (Riising et al., 2014), other chromatin modifiers
(DNMTs, EHMT1/2, MLL2/SET1A, HUSH), nucleosome remodelers (NuRD, NURF, NoRC, CHRAC, NuA4, INO80, BAF, ATRX/
DAXX), regulators of higher-order structure (cohesin, CTCF,
SMCHD1, SAFB), and transcription factors (including POU5F1
[OCT4], ZFP57, UBTF, TP53, MYBL2 and UTF1). Surprisingly,
we also found that a number of regulators of RNA Pol II processivity, including P-TEFb and other components of the superelongation complex (SEC), PPP2C1 (PP2A), BRD4, and Integrator, were recruited to chromatin upon RNA Pol II inhibition,
with P-TEFb exhibiting particularly large increases in chromatin
association (Figure 1C). Immunoblotting for representative proteins in cell fractions generated using a different biochemical
method confirmed RNA Pol II inhibition induced changes in chromatin association for 16 of the 22 proteins tested (73%) and validated that changes in chromatin association were not an artifact
of changes in total protein abundance (Figure 1D; Table S1).
We considered that if the changes in the association of proteins with chromatin were the direct effects of changes in transcription, then restarting transcription should begin to reverse
the changes. We therefore also analyzed cells harvested 3 h after
flavopiridol had been washed out after the initial 3-h incubation
(Figures 1E and S1L). This showed that removing flavopiridol
and allowing transcriptional elongation to restart began to
reverse the changes caused by flavopiridol treatment (r =
0.34, p = 8.5 3 1016), although the magnitude of the effect
was small relative to the initial treatment. Taking these data
together, we conclude that transcription acts in a dynamic
manner to regulate the association of a specific set of chromatin
and transcriptional regulatory proteins with chromatin.
RNA degradation has similar effects to RNA Pol II
inhibition on the interaction of proteins with chromatin
Some of the changes observed upon transcriptional inhibition
could reflect the loss of nascent RNA, but others could reflect
loss of the process of transcription and its associated histone
modifications. That nascent RNA inhibits the association of
PRC2 with chromatin is demonstrated by its recruitment to chromatin upon both RNA Pol II inhibition (Riising et al., 2014) and
RNaseA treatment (Beltran et al., 2016). Therefore, we considered that the effects of RNA Pol II inhibition due to the loss of
nascent RNA should also be observed upon the degradation of
RNA in cells with RNaseA. To test this, we permeabilized ESCs
and either mock-treated or treated with RNaseA. RNA-seq revealed that this reduced the level of chromatin-associated intronic transcripts by a median of 146-fold, but reduced polyA+
exonic RNA by only 1.3-fold (Figures S2A and S2B). The reason
for this differential effect is unclear, but it may represent protection of mature mRNA by ribosomes or other RNA-binding
proteins.
We then quantified the change in protein association with the
chromatin fraction using label-free LC-MS/MS (Figures 2A and
S2C; Table S3). As we had observed upon the inhibition of
RNA Pol II, RNA degradation caused the loss of factors involved
in RNA processing from chromatin and recruitment of a set of
transcriptional and chromatin regulators (Figures 2B; Table S4).
Taking the proteins altered by RNA Pol II inhibition and
comparing the changes with those caused by RNA degradation
revealed a significant correlation (r = 0.45, p = 4.9 3 1028, Figures 2C and S2D) and significant overlaps (Figure S2E; 47% of
proteins significantly depleted from chromatin after RNA Pol II inhibition were also significantly depleted [FDR < 0.05] from chromatin after RNaseA treatment [p = 83 3 1045, hypergeometric];
24% of proteins significantly enriched on chromatin after RNA
Pol II inhibition were also significantly enriched [FDR < 0.05] on
chromatin after RNaseA treatment [p = 1.6 3 104]). Immunoblotting demonstrated that the regulatory proteins we had previously confirmed to be recruited to chromatin or depleted from
chromatin in response to RNA Pol II inhibition exhibited the
same changes in chromatin association upon RNA depletion
(Figure 2E).
Not all of the changes in chromatin composition induced by
RNA Pol II inhibition were recapitulated by RNA degradation.
(C) Changes in the association of proteins with chromatin upon RNA Pol II inhibition (average of 9-h flavopiridol and triptolide data) and RNA degradation relative
to their respective control samples (scale below). Proteins were either recruited to chromatin or depleted from chromatin after both flavopiridol and triptolide
treatments. The change in protein chromatin association in response to RNA degradation is shown below and is correlated (r = 0.45, p = 4.9 3 1028, n = 527).
(D) Change in chromatin association caused by RNA degradation for the proteins and complexes shown in Figure 1C. Details as for Figure 1C.
(E) Immunoblots for proteins representative of those shown in (D) in the cytoplasmic, nucleoplasmic, and chromatin fractions and WCE purified from ESC after
mock treatment () or treatment with RNaseA (+).
See also Figure S2 and Tables S3 and S4.
Molecular Cell 81, 1–16, July 15, 2021 5
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
For a minority of factors, RNA degradation had the opposite effect of RNA Pol II inhibition. Rather than being recruited to chromatin, as occurred in response to RNA Pol II inhibition, the THO
complex, and Scaffold attachment factor B (SAFB) factors were
lost from chromatin upon RNA degradation (Figure 2D), potentially indicating an association with chromatin via stable RNAs.
Reciprocally, the PAF complex, which was depleted from chromatin upon RNA Pol II inhibition, was recruited to chromatin
upon RNA degradation (Figures S2F and S2G). We conclude
that many of the changes in protein chromatin association
caused by RNA Pol II inhibition are recapitulated by RNA degradation, suggesting a role for nascent RNA, but that other
changes are specific to one of the two treatment types.
RNA antagonizes the interaction of a set of chromatin
regulators with nucleosomes
RNA Pol II inhibition and RNA degradation in cells are likely to
have pleiotropic effects. Thus, we sought further evidence that
RNA inhibited the interaction of chromatin regulatory proteins
with chromatin. The antagonistic effect of transcription on the
association of PRC2 with chromatin reflects the inhibitory effect
of RNA on PRC2 binding to nucleosomes (Beltran et al., 2016,
2019; Wang et al., 2017b). We thus considered that RNA may
also antagonize nucleosome binding by the other chromatin regulatory proteins identified in our proteomics analysis. To test this
in an unbiased manner, we purified nuclear extract from ESCs,
either mock-treated the extract or treated it with RNaseA, incubated the extracts with biotinylated dinucleosomes, purified
the nucleosomes with streptavidin beads, and then quantified interacting proteins using SILAC (Figures 3A, S3A, and S3B; Table
S5). We identified a set of proteins that exhibited increased binding and a set of proteins that exhibited decreased binding (FDR <
0.05) to nucleosomes after RNA degradation (Figure 3B). Mirroring the effect of RNA Pol II inhibition in cells, the GO term Chromatin Organization was enriched (p = 0.0017; Table S6) in the set
of proteins that exhibited increased binding to nucleosomes after RNA degradation. Furthermore, there was a significant overlap between the sets of proteins that exhibited increased binding
to nucleosomes after RNA degradation and those that exhibited
increased association with chromatin upon RNA Pol II inhibition
(26% of proteins enriched on nucleosomes after RNA degradation in vitro were also enriched on chromatin after RNA Pol II inhibition in cells; p = 0.027; Figures 3C and S3C). However, differences were also noted. In addition to the chromatin regulators
identified in the RNA Pol II inhibition experiment, RNA depletion
also increased nucleosome binding by the non-canonical PRC1
complex PRC1.6, the non-specific lethal (NSL) and Ada Two A
containing (ATAC) histone acetyltransferase complexes, and
the NCOR1, NCOR2, CtBP/LSD1, MiDAC, SIN3A, ING2, and
CAF-1 histone deacetylase complexes (Figure 3C), which were
either under the significance threshold or were not detected in
the cellular chromatin-binding experiments.
To confirm the proteomics results and to distinguish whether
RNA inhibited the interaction of the proteins with the core nucleosome particle or with linker DNA, we repeated the experiment
with either dinucleosomes, mononucleosomes incorporating
linker DNA (185 bp), or mononucleosomes lacking linker DNA
(147 bp) and measured changes in nucleosome interaction by
6 Molecular Cell 81, 1–16, July 15, 2021
immunoblotting (Figures 3D and S3D; Table S5). Of the 16 proteins we tested, 13 were enriched by nucleosome affinity purification, and all of these exhibited increased nucleosome binding
upon RNA degradation, including CHD1, CHD4, INO80, EHMT1,
SMARCC1, and RUVBL2, thus validating the proteomics data.
This experiment also confirmed that RNA antagonized the interaction of PRC2 (SUZ12) with nucleosomes, which did not reach
significance (FDR < 0.05) in the proteomics analysis. In contrast,
and also consistent with the proteomics data, HMGN1 exhibited
decreased binding to nucleosomes upon RNA degradation.
Furthermore, these results were apparent for all types of nucleosomes tested, suggesting that RNA modulates the interaction of
these factors with the core nucleosome particle rather than with
linker DNA. We conclude that nuclear RNA inhibits the association of a set of regulatory proteins with nucleosomes, be this
blocking direct interaction with nucleosomes or indirect interaction via a protein partner.
We next considered that if the increase in the binding of these
proteins to nucleosomes after RNA degradation reflects the
antagonism of nucleosome binding by RNA, then this should
be reversed by the re-addition of RNA. Because PRC2 promiscuously binds complex RNAs (Davidovich et al., 2013), tRNA
can be used to model the competition between RNA and nucleosomes for PRC2 binding (Beltran et al., 2016). We therefore
asked whether the increase in the nucleosome binding of other
chromatin regulators upon RNA degradation could also be
reversed by the addition of tRNA. To test this, we added tRNA
and RNase inhibitor to the RNaseA-treated nuclear extracts
and repeated the nucleosome affinity purification and proteomics analysis (Figures 3E and S3E). We found that this generally
reversed the changes in nucleosome binding caused by RNA
degradation (r = 0.34, p = 3.7 3 1019), demonstrating that
RNA antagonizes the interaction of this set of regulatory proteins
with chromatin.
Direct interaction of chromatin regulators with RNA
in cells
RNA inhibits the interaction of PRC2 with chromatin because it
directly competes with nucleosomes for PRC2 binding (Beltran
et al., 2016, 2019; Wang et al., 2017b). Thus, we asked whether
the antagonistic effect of RNA on the interaction of regulatory
complexes with chromatin could reflect direct interaction between these proteins and RNA. To test this, we selected a set of
eight proteins representative of the factors that exhibited
increased chromatin binding after RNA degradation: the NuRD
component CHD4, the INO80 component INO80, the INO80
and NuA4 component RUVBL2, the BAF components SMARCC1
and SMARCA4, EHMT1, the HMG box transcription factor UBTF,
and the integrator subunit INTS11 and used cross-linking and
immunoprecipitation (CLIP) to determine whether these proteins
directly bound RNA in cells. We detected direct RNA binding for
six of these eight proteins in cells (Figures 4A and S4). This was
evidenced by the detection of an RNP of the expected molecular
weight, with a smear of trimmed RNA extending above, which was
stronger in +UV and +PNK (polynucleotide kinase) conditions and
which diminished as the RNaseI concentration was increased.
To explore this on a more global scale, we compared the
sets of proteins that were depleted or recruited to chromatin
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
A
B
C
D
E
Figure 3. RNA antagonizes the interaction of a set of chromatin regulators with nucleosomes
(A) Experimental strategy. ESC nuclear extract was mock-treated or treated with RNaseA and incubated with biotinylated dinucleosomes, which were then
purified by streptavidin affinity purification and bound proteins quantified by SILAC.
(B) Significance of changes in the association of proteins with nucleosomes upon RNaseA treatment versus mock-treated control. Proteins with functions in RNA
processing and chromatin organization are highlighted in blue or red, respectively, and their frequencies in the sets of proteins that showed decreased or
increased nucleosome binding (FDR < 0.05) shown above.
(C) Chromatin modifiers and nucleosome remodeler complexes that exhibit a significant number of subunits with increased nucleosome binding after degradation
of RNA in nuclear extract. Changes in the association of proteins with nucleosomes versus the mock-treated sample are indicated by color, according to the scale
on the right, and by the outline (black FDR < 0.05, white FDR > 0.05). Proteins detected in the RNA Pol II inhibition experiment but not this experiment are in gray.
(D) Immunoblots for proteins representative of those shown in (C) in nucleosome pull-downs (dinucleosomes, or mononucleosomes assembled with 187 or
147 bp DNA) from mock-treated () or RNaseA-treated (+) nuclear extracts.
(E) Top, strategy: tRNA and RNase inhibitor were added to nuclear extracts after RNaseA-treatment. Bottom: proteins exhibiting either significantly increased or
decreased interaction with nucleosomes after RNaseA degradation. Change in nucleosome interaction after tRNA addition is shown below and is anti-correlated
(r = 0.34, p = 3.7 3 1019, n = 668).
See also Figure S3 and Tables S5 and S6.
Molecular Cell 81, 1–16, July 15, 2021 7
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
A
B
Figure 4. Direct interaction of chromatin regulators with RNA in cells
(A) SDS-PAGE for RNPs enriched by CLIP for CHD4, INO80, RUVBL2, SMARCC1, EHMT1, UBTF, and non-specific immunoglobulin G (IgG) controls in ESCs.
Autoradiograms of crosslinked 32P-labeled RNA are shown at the top and the corresponding immunoblots below. CLIP was performed with and without UV
crosslinking and polynucleotide kinase (PNK) and with high (H; 40 U/mL) or low (L; 4 U/mL) concentrations of RNase I. The arrows indicate the molecular weight of
the protein of interest.
(B) Proportion of proteins exhibiting a significant increase on chromatin (FDR < 0.05, n = 281), decrease on chromatin (FDR < 0.05, n = 241), or no change on
chromatin (FDR > 0.05, n = 617) upon treatment with flavopiridol and triptolide (9 h) that were identified as binding RNA in the indicated studies. Studies are
divided into those that could only detect binding to polyA+ RNA and those that could also detect binding to non-polyA+ RNA. For each study, significance is
estimated relative to the proportion of non-changing proteins identified to bind RNA (binomial test with Bonferroni correction).
See also Figure S4.
8 Molecular Cell 81, 1–16, July 15, 2021
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
upon RNA Pol II inhibition with proteins identified to bind RNA
in 12 previous screens, 8 of which identified proteins bound to
mature polyadenylated RNA (Baltz et al., 2012; Beckmann
et al., 2015; Castello et al., 2012, 2016; Conrad et al., 2016;
Kwon et al., 2013; Mullari et al., 2017; Perez-Perri et al.,
2018) and 4 of which could also identify proteins bound to
nascent RNA or other non-polyadenylated transcripts (Bao
et al., 2018; Caudron-Herger et al., 2019; He et al., 2016; Trendel et al., 2019). We found that the set of proteins depleted
from chromatin was significantly enriched for RBPs identified
by all of the studies (Figure 4B). Then, focusing on the set of
proteins recruited to chromatin upon RNA Pol II inhibition, we
found that this was significantly enriched for RBPs identified
by all four studies that could measure non-polyadenylated
RNA binding, including a study that specifically identified proteins bound to nascent RNA (Bao et al., 2018). The set of proteins recruited to chromatin upon RNA Pol II inhibition was also
enriched for RBPs identified by three of the eight studies that
were limited to polyA+ RNA, albeit to a lesser extent. Together
with our CLIP data, these results suggest that the inhibitory effect of RNA on the interaction of these proteins with chromatin
is due to the interaction of these factors with RNA.
P-TEFb interacts with nascent pre-mRNA in cells
The P-TEFb subunits CDK9, CyclinT1, and CyclinT2 were among
the proteins exhibiting the greatest increases in chromatin association upon RNA Pol II inhibition and RNaseA treatment (Figures
1C and 2D). We hypothesized that the antagonistic effect of RNA
on P-TEFb chromatin binding could reflect the interaction of PTEFb with RNA. Consistent with this possibility, CyclinT1 directly
contacts HIV TAR RNA when in a complex with HIV Tat (Garber
et al., 1998; Richter et al., 2002; Wei et al., 1998). We tested
whether P-TEFb bound to RNA in ESC by performing individual-nucleotide-resolution UV CLIP (iCLIP) for P-TEFb using an
antibody specific to CDK9. This resulted in the co-precipitation
of CyclinT1 and revealed a UV-dependent RNP that matched
the molecular weight of CyclinT1 (Figure S5A). This RNP could
also be observed by CLIP with an antibody to CyclinT1 (Figure S5B) and was depleted upon the degradation of CDK9 using
THAL-SNS-032, demonstrating it to be dependent on P-TEFb
(Figure S5C). We conclude that P-TEFb interacts with RNA in
cells. Although the size of the RNP corresponds to CyclinT1,
we cannot rule out that other proteins that interact with P-TEFb
also contribute to this signal.
Sequencing of P-TEFb RNA crosslink sites revealed strong
enrichment for 7SK RNA (Figure S5D), as expected, given its
role in sequestering P-TEFb. However, we found that the majority of P-TEFb crosslinks mapped to protein-coding genes with
enrichment around 50 splice sites (50 SS) that was not observed
in the background RNA crosslinking from input control samples
(Figures 5A and S5E). CLIP for CDK9 did not co-precipitate the
7SK RNP component LARP7 (Figure S5F) and crosslinking
around 50 SS was not observed in iCLIP experiments for LARP7
(Figures 5A and S5G), demonstrating that P-TEFb was not binding to pre-mRNA as part of the 7SK RNP. iCLIP for P-TEFb did
not enrich for small nuclear RNAs (snRNAs), suggesting that
the crosslinking detected around 50 SS does not reflect the coprecipitation of spliceosome components (Figure S5D).
Given the enrichment of P-TEFb RNA crosslinking around
50 SS, we considered that P-TEFb binding to RNA may be dependent on splicing. To test this, we compared P-TEFb crosslinking
at 50 SS at exons included in the mature transcript versus exons
that were excluded (Figures 5B and S5H). We found that P-TEFb
RNA crosslinking was only apparent at included exons, consistent with this crosslinking being dependent on splicing. Furthermore, P-TEFb exhibited reduced crosslinking to RNA transcribed from single-exon compared to multi-exon genes
(Figure S5I). To confirm a requirement for splicing, we repeated
CDK9 iCLIP after treatment of cells with the SF3b inhibitor pladienolide B (pla-B, 1 mM for 6 h) (Figure 5C). We found that the
specific pattern of P-TEFb crosslinking around 50 SS was not
observed after treatment with pla-B and conclude that P-TEFb
directly binds nascent pre-mRNA around 50 SS and that this is
dependent on splicing.
7SK RNA regulates the interaction of P-TEFb with
nascent RNA and chromatin
We sought to understand the factors that regulate the interaction
of P-TEFb with RNA or chromatin. P-TEFb is held in a poised
state by the 7SK RNP, from which it is released to activate transcriptional elongation (Bacon and D’Orso, 2019; Quaresma
et al., 2016). The lack of enrichment of the core 7SK RNP component LARP7 with nascent RNA indicated that P-TEFb interacted
with nascent RNA in its free, non-7SK associated form. We
considered that if this was the case, then the depletion of 7SK
RNA should increase P-TEFb binding to nascent RNA. To test
this, we performed CLIP for P-TEFb in ESCs transfected with
antisense locked nucleic acid (LNA) oligonucleotides specific
for 7SK RNA or scrambled control oligos (Figures 6A and S6A).
We found that knock down of 7SK increased P-TEFb RNA binding (p = 0.008, Welch’s t test), but, in contrast, it had no effect on
the binding of LARP7 to RNA. This demonstrates that P-TEFb
binds nascent RNA in its free form, and this is countered by its
interaction with 7SK.
Given that 7SK antagonized the association of P-TEFb with
nascent RNA, we hypothesized that the transfer of P-TEFb to
chromatin upon RNA Pol II inhibition may also be regulated by
7SK (transcribed by RNA Pol III). To test this, we measured the effect of RNA Pol II inhibition on the association of P-TEFb with chromatin in WT HAP1 cells and in HAP1 cells in which 7SK is deleted
(Studniarek et al., 2021). We found that treatment with triptolide
increased the association of P-TEFb with the chromatin fraction
in wild-type (WT) cells but not in 7SK knockout (KO) cells (p <
0.05, Student’s t test; Figures 6B and 6C). In contrast, SMARCC1
increased in the chromatin fraction in both WT and 7SK KO cells,
while LARP7 showed no change. Thus, 7SK is required for the
recruitment of P-TEFb to chromatin upon RNA Pol II inhibition.
The 7SK RNP associates with chromatin at active genes
through interaction with KAP1 (McNamara et al., 2016). We
therefore considered that the transfer of P-TEFb to chromatin
upon RNA Pol II inhibition may depend on KAP1. To test this,
we measured the effect of triptolide treatment on P-TEFb chromatin association in WT and KAP1 KO cells. We found that in
the absence of KAP1, the extent of P-TEFb recruitment to chromatin was approximately halved (p < 0.05, Student’s t test; Figures 6D and 6E), indicating that the association of 7SK with
Molecular Cell 81, 1–16, July 15, 2021 9
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
Figure 5. P-TEFb directly interacts with
nascent pre-mRNA in cells
A
(A) Average P-TEFb (red), LARP7 (blue), and
background input (black) RNA crosslinking
around 50 splice sites (SS) at first and mid exons
and 30 SS at mid and last exons within nascent
RNAs at all genes.
(B) Average P-TEFb (red) band background input
(black) RNA crosslinking around 50 SS at excluded
and included exons.
(C) Average P-TEFb RNA crosslinking at 50 SS in
cells treated with DMSO or pladienolide B (pla-B).
See also Figure S5.
DISCUSSION
B
C
genes facilitates the recruitment of P-TEFb to chromatin upon
RNA Pol II inhibition. We explored whether the requirement for
7SK and KAP1 for the recruitment of P-TEFb to chromatin
upon RNA Pol II inhibition was because P-TEFb became associated with 7SK on chromatin. However, CyclinT1 immunoprecipitation from the chromatin fraction revealed a reduction in
P-TEFb interaction with 7SK RNA and LARP7 after RNA Pol II inhibition (Figure S6B). Thus, 7SK is necessary for the transfer of
P-TEFb to chromatin upon transcriptional inhibition but does
not itself constitute the chromatin-associated P-TEFb pool in
transcriptionally inactive cells. These data support a model in
which nascent RNA binds to a set of transcriptional and chromatin regulators and inhibits their association with chromatin,
which, in the case of P-TEFb, is regulated by the 7SK RNP
(Figure 6F).
10 Molecular Cell 81, 1–16, July 15, 2021
The antagonistic effect of RNA on the
interaction of PRC2 with chromatin has
been demonstrated by experiments using RNA Pol II inhibition, RNA degradation, and nucleosome-RNA competition
assays (Beltran et al., 2016, 2019; Riising
et al., 2014; Wang et al., 2017b). By
adapting these methods to allow a
more systematic analysis, we have revealed that the antagonistic effect of
nascent RNA on PRC2 function is an
example of a broader role for RNA in inhibiting the interaction of transcriptional
and chromatin regulator proteins with
chromatin. That nascent RNA inhibits
the association of DNMT1 and DNMT3A
with chromatin is consistent with previous data demonstrating that RNA inhibits the activity of these enzymes (Di
Ruscio et al., 2013; Hendrickson et al.,
2016; Savell et al., 2016), while the identification of BAF is consistent with previous reports that RNA inhibits its interaction with nucleosomes (Cajigas et al.,
2015; Han et al., 2014; Jégu et al.,
2019; Prensner et al., 2013). That RNA inhibits the interaction of cohesin with
chromatin is potentially consistent with previous findings that
transcription inhibition induces cohesin accumulation at intragenic sites (Heinz et al., 2018). RNA has not previously been reported to antagonize the interaction of other proteins identified
here with chromatin, although a number of the factors have previously been found to bind RNA, including MLL/SET complexes
(Wang et al., 2011), BRD4 (Rahnamoun et al., 2018), Integrator
(Baillat et al., 2005), INO80 subunits (Davidovic et al., 2006;
Jeon and Lee, 2011; Sigova et al., 2015), NuRD (Hendrickson
et al., 2016; Zhao et al., 2016), NoRC and CHRAC (Hu et al.,
2019; Mayer et al., 2006), cohesin (Hendrickson et al., 2016; Li
et al., 2013; Pan et al., 2020; Tsai et al., 2018), CTCF (Hansen
et al., 2019; Kung et al., 2015; Saldaña-Meyer et al., 2014),
SMCHD1 (Chen et al., 2015), and SAFB (Rivers et al., 2015).
The set of proteins identified to be antagonized by RNA is
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
A
C
B
D
E
F
Figure 6. 7SK RNA regulates the interaction of P-TEFb with nascent RNA and chromatin
(A) Left: SDS-PAGE for RNPs enriched by CLIP for P-TEFb and LARP7 in ESCs transfected with scrambled antisense oligonucleotide (ASO) or ASO specific for
7SK RNA. Autoradiograms of crosslinked RNA are shown at the top and immunoblots below. Right: quantification of the change in RNA crosslinking (7SK ASO
versus scrambled ASO) relative to protein (means ±SDs, n = 7 [P-TEFb] or n = 2 [LARP7], 1-sided Welch’s t test).
(B) Immunoblots for CyclinT1 (CCNT1), CDK9, LARP7, SMARCC1, and control proteins in cytoplasmic, nucleoplasmic, and chromatin fractions and WCE from
WT and 7SK KO HAP1 cells after incubation with triptolide for 0, 3, and 6 h.
(C) Quantification of immunoblots shown in (B), measuring chromatin association of each protein relative to t = 0 (means ± SDs, 1-sided Student’s t test, 4 independent experiments).
(D) Immunoblots in cytoplasmic, nucleoplasmic, and chromatin fractions and WCE from WT and KAP1 KO HEK293T cells after incubation with triptolide for 0, 3,
and 6 h.
(E) Quantification of immunoblots shown in (E), measuring chromatin association of each protein relative to t = 0 (means ± SDs, 1-sided Student’s t test, 3 independent experiments).
(F) Model: nascent RNA binds a set of transcriptional and chromatin regulators and antagonizes their association with chromatin. For some of these factors, RNA
inhibits their interaction with nucleosomes. For P-TEFb, RNA binding and recruitment to chromatin are regulated by the 7SK RNP.
See also Figure S6.
Molecular Cell 81, 1–16, July 15, 2021 11
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
enriched for functions in ESC pluripotency, and a number of the
factors share subunits and/or function together in common pathways—for example, PRC2 with NuRD (Reynolds et al., 2012) and
INO80 (Xue et al., 2017)—suggesting that nascent RNA regulates
the interaction of factors with chromatin in a coordinated
manner.
Of the factors we identified to be regulated by nascent RNA,
we focused on P-TEFb because its subunits were among the
proteins exhibiting the greatest increases in chromatin association upon RNA Pol II inhibition and because it had previously
been shown to directly bind HIV TAR RNA (Garber et al., 1998;
Richter et al., 2002). The RNA Pol II Ser-2 kinases Ctk1 and
Bur1 have also been found to directly bind nascent RNA in
Saccharomyces cerevisiae, suggesting that nascent RNA binding activity is conserved in eukaryotes (Battaglia et al., 2017).
However, in yeast, RNaseA treatment reduced rather than
increased the association of Ctk1 and Bur1 with chromatin (Battaglia et al., 2017), potentially reflecting differences in the mechanisms of chromatin association between species.
Our discovery that nascent pre-mRNA interacts with P-TEFb
and antagonizes its association with chromatin suggests that
cellular pre-mRNA may act in a manner analogous to that of
TAR, which releases the Tat:P-TEFb complex from the 7SK
RNP (D’Orso and Frankel, 2010). The RNA-binding proteins
SRSF2 (Ji et al., 2013), DDX21 (Calo et al., 2015), WDR43 (Bi
et al., 2019), and RBM7 (Bugai et al., 2019) have been found to
release P-TEFb from 7SK and increase RNA Pol II Ser-2P, and
thus may act in a manner analogous to that of Tat. In particular,
SRSF2 both promotes splicing and P-TEFb recruitment to genes
(Ji et al., 2013; Lin et al., 2008), which is potentially consistent
with the requirement for splicing for P-TEFb binding to 50 SS.
Further studies will be required to ascertain the importance of
nascent RNA binding for P-TEFb function. Interaction of P-TEFb
with nascent pre-mRNA could increase the size of the free PTEFb pool or could specifically direct its activities to particular locations or substrates. For example, P-TEFb binding to internal
sites within pre-mRNA could function to maintain Ser-2P as
RNA Pol II travels through the gene body. More specifically,
the splicing-dependent enrichment of P-TEFb at 50 SS may
help couple splicing with transcriptional elongation (Herzel
et al., 2017) and may contribute to previously observed stimulatory effects of splicing on Ser-2P and transcriptional elongation
(Caizzi et al., 2021; Chathoth et al., 2014; Fong and Zhou,
2001; Ji et al., 2013; Koga et al., 2015; Lin et al., 2008).
Limitations of the study
We recognize that RNA Pol II inhibition and RNA degradation
likely have pleiotropic effects on the cell, and thus we sought
to identify changes in protein chromatin association that were
common to both treatments and also complemented these
cellular treatments with measurement of the effect of RNA depletion from nuclear extracts on the interaction of proteins with nucleosomes. RNA Pol II inhibition and RNA degradation had a
greater effect on nascent transcripts than on mature polyA+
RNA species, suggesting that changes in the interaction of proteins with chromatin are primarily due to the loss of nascent RNA,
but it is possible that some of the effects are caused by the loss
of short-lived mature RNAs. The experimental design also does
12 Molecular Cell 81, 1–16, July 15, 2021
not distinguish between the effects of pre-mRNAs versus other
nascent RNA species. However, it is likely that much of the effect
is due to pre-mRNAs because these represent the majority of
nascent and chromatin-associated RNAs in the cell (Mondal
et al., 2010; Nozawa and Gilbert, 2019; St Laurent et al., 2012)
and, where known, the majority of RNAs bound by the factors
identified here, including PRC2 (Beltran et al., 2016), DNMT1
(Hendrickson et al., 2016), DNMT3A (Savell et al., 2016), the
NuRD components CHD4 and HDAC1 (Hendrickson et al.,
2016), and P-TEFb (this study). Further work will be necessary
to determine the RNA species bound by the factors identified,
the binding sites on chromatin affected by RNA, and the importance of RNA binding activity for the function of the proteins in
the cell. In the case of P-TEFb, further work is necessary to identify the factor(s) that mediate its association with chromatin upon
RNA Pol II inhibition.
In summary, our work demonstrates that nascent RNA regulates the interaction of a set of chromatin and transcriptional regulatory factors with chromatin and primarily acts to antagonize
their interaction with chromatin. These results are consistent
with models in which nascent RNA provides direct feedback
from gene transcription to chromatin state (Skalska et al.,
2017) and provides evidence of a close interplay between RNA
and chromatin in gene regulation. Nascent RNAs and other transcripts have been proposed to contribute to a dynamic matrix or
phase-separated compartments that regulate chromatin state
(Hnisz et al., 2017; Nozawa and Gilbert, 2019). Thus, these structures may function in part by concentrating the antagonistic effects of RNA at regions of active chromatin in the cell.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d
d
d
d
d
KEY RESOURCES TABLE
RESOURCE AVAILABILITY
B Lead contact
B Materials availability
B Data and code availability
EXPERIMENTAL MODEL AND SUBJECT DETAILS
METHOD DETAILS
B Cell fractionation for proteomics experiments
B Nucleosome affinity purification for proteomics
B SILAC
B Label-free quantification (LFQ)
B Cell fractionation for validation experiments
B Nucleosome affinity purification validation
B Immunoblotting
B 7SK knockdown
B CLIP
B iCLIP
B Co-immunoprecipitation from chromatin
B RNA-seq
B Cell cycle, caspase activation, cell death, gH2A.X
QUANTIFICATION AND STATISTICAL ANALYSIS
B Mass-spectrometry data analysis
B LC-MS/MS data post-processing and analysis
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
iCLIP data analysis
RNA-seq analysis
B Comparison to RNA binding studies
B CLIP and immunoblotting
B
B
SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.
molcel.2021.05.026.
ACKNOWLEDGMENTS
This work was supported by the UCL Cancer Institute Genomics TTP and Bill
Lyons Informatics Centre, funded by the Cancer Research UK–UCL Centre
(award no. C416/A25145) and by the Proteomics Research TTP, funded by
the Cancer Research UK–UCL Centre (C416/A25145) and the Cancer
Research UK Cancer Immunotherapy Network Accelerator (CITA) (C33499/
A20265). Thanks to Sylvain Egloff for the 7SK KO HAP1 cells, Helen Rowe
for the KAP1 KO HEK293T cells, Juan Garcı́a Gómez for help with the DNA
damage experiments, and Maria Vila de Mucha for assistance with flow cytometry. The research was funded by grants from the European Research Council
(ERC, 311704), Blood Cancer UK (18008), and Worldwide Cancer Research
(21-0255), to R.G.J., and from the ERC (309952) and the Helmholtz Society,
to T.B.
AUTHOR CONTRIBUTIONS
Conceptualization, L.S., M.B., and R.G.J.; methodology, L.S., M.B., and
R.G.J.; software, S.L. and G.K.; validation, L.S., V.B., M.B., and R.W.; formal
analysis, V.B., S.L., G.K., P.F., S.S., and R.G.J.; investigation, L.S., M.B.,
V.B., P.F., A.B., M.T., and R.W.; resources, L.S., A.T., B.M.F., J.H., and
A.P.S.; data curation, V.B., S.L., G.K., P.F., I.R.D.L.M., S.S., and R.G.J.; writing
– original draft, R.G.J.; writing – review & editing, L.S., V.B., M.B., S.L., T.B.,
and R.G.J.; visualization, L.S., V.B., M.B., S.L., G.K., M.T., and R.G.J.; supervision, J.H., S.S., A.P.S., T.B., and R.G.J.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: May 21, 2020
Revised: May 19, 2021
Accepted: May 23, 2021
Published: June 23, 2021
REFERENCES
Bacon, C.W., and D’Orso, I. (2019). CDK9: a signaling hub for transcriptional
control. Transcription 10, 57–75.
€a
€r, A.M., Shilatifard, A., Cooch, N., and
Baillat, D., Hakimi, M.A., Na
Shiekhattar, R. (2005). Integrator, a multiprotein mediator of small nuclear
RNA processing, associates with the C-terminal repeat of RNA polymerase
II. Cell 123, 265–276.
€usser, B., Vasile, A., Murakawa, Y.,
Baltz, A.G., Munschauer, M., Schwanha
Schueler, M., Youngs, N., Penfold-Brown, D., Drew, K., Milek, M., et al.
(2012). The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. Mol. Cell 46, 674–690.
Bao, X., Guo, X., Yin, M., Tariq, M., Lai, Y., Kanwal, S., Zhou, J., Li, N., Lv, Y.,
Pulido-Quetglas, C., et al. (2018). Capturing the interactome of newly transcribed RNA. Nat. Methods 15, 213–220.
Barboric, M., Yik, J.H., Czudnochowski, N., Yang, Z., Chen, R., Contreras, X.,
Geyer, M., Matija Peterlin, B., and Zhou, Q. (2007). Tat competes with HEXIM1
to increase the active pool of P-TEFb for HIV-1 transcription. Nucleic Acids
Res. 35, 2003–2012.
Barutcu, A.R., Blencowe, B.J., and Rinn, J.L. (2019). Differential contribution of
steady-state RNA and active transcription in chromatin organization. EMBO
Rep. 20, e48068.
Battaglia, S., Lidschreiber, M., Baejen, C., Torkler, P., Vos, S.M., and Cramer,
P. (2017). RNA-dependent chromatin association of transcription elongation
factors and Pol II CTD kinases. eLife 6, e25637.
Beckmann, B.M., Horos, R., Fischer, B., Castello, A., Eichelbaum, K.,
Alleaume, A.M., Schwarzl, T., Curk, T., Foehr, S., Huber, W., et al. (2015).
The RNA-binding proteomes from yeast to man harbour conserved
enigmRBPs. Nat. Commun. 6, 10127.
Beltran, M., Yates, C.M., Skalska, L., Dawson, M., Reis, F.P., Viiri, K., Fisher,
C.L., Sibley, C.R., Foster, B.M., Bartke, T., et al. (2016). The interaction of
PRC2 with RNA or chromatin is mutually antagonistic. Genome Res. 26,
896–907.
Beltran, M., Tavares, M., Justin, N., Khandelwal, G., Ambrose, J., Foster, B.M.,
Worlock, K.B., Tvardovskiy, A., Kunzelmann, S., Herrero, J., et al. (2019). Gtract RNA removes Polycomb repressive complex 2 from genes. Nat. Struct.
Mol. Biol. 26, 899–909.
Bi, X., Xu, Y., Li, T., Li, X., Li, W., Shao, W., Wang, K., Zhan, G., Wu, Z., Liu, W.,
et al. (2019). RNA Targets Ribogenesis Factor WDR43 to Chromatin for
Transcription and Pluripotency Control. Mol. Cell 75, 102–116.e9.
€ster, R., Sibley, C.R.,
Bugai, A., Quaresma, A.J.C., Friedel, C.C., Lenasi, T., Du
Fujinaga, K., Kukanja, P., Hennig, T., Blasius, M., et al. (2019). P-TEFb
Activation by RBM7 Shapes a Pro-survival Transcriptional Response to
Genotoxic Stress. Mol. Cell 74, 254–267.e10.
Caizzi, L., Monteiro-Martins, S., Schwalb, B., Lysakovskaia, K., Schmitzova,
J., Sawicka, A., Chen, Y., Lidschreiber, M., and Cramer, P. (2021). Efficient
RNA polymerase II pause release requires U2 snRNP function. Mol. Cell 81,
1920–1934.e9.
Cajigas, I., Leib, D.E., Cochrane, J., Luo, H., Swyter, K.R., Chen, S., Clark,
B.S., Thompson, J., Yates, J.R., 3rd, Kingston, R.E., and Kohtz, J.D. (2015).
Evf2 lncRNA/BRG1/DLX1 interactions reveal RNA-dependent inhibition of
chromatin remodeling. Development 142, 2641–2652.
Calo, E., Flynn, R.A., Martin, L., Spitale, R.C., Chang, H.Y., and Wysocka, J.
(2015). RNA helicase DDX21 coordinates transcription and ribosomal RNA
processing. Nature 518, 249–253.
Castello, A., Fischer, B., Eichelbaum, K., Horos, R., Beckmann, B.M., Strein,
C., Davey, N.E., Humphreys, D.T., Preiss, T., Steinmetz, L.M., et al. (2012).
Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.
Cell 149, 1393–1406.
Castello, A., Fischer, B., Frese, C.K., Horos, R., Alleaume, A.M., Foehr, S.,
Curk, T., Krijgsveld, J., and Hentze, M.W. (2016). Comprehensive
Identification of RNA-Binding Domains in Human Cells. Mol. Cell 63, 696–710.
Caudron-Herger, M., Rusin, S.F., Adamo, M.E., Seiler, J., Schmid, V.K.,
Barreau, E., Kettenbach, A.N., and Diederichs, S. (2019). R-DeeP:
Proteome-wide and Quantitative Identification of RNA-Dependent Proteins
by Density Gradient Ultracentrifugation. Mol. Cell 75, 184–199.e10.
Chathoth, K.T., Barrass, J.D., Webb, S., and Beggs, J.D. (2014). A splicingdependent transcriptional checkpoint associated with prespliceosome formation. Mol. Cell 53, 779–790.
Chen, K., Hu, J., Moore, D.L., Liu, R., Kessans, S.A., Breslin, K., Lucet, I.S.,
Keniry, A., Leong, H.S., Parish, C.L., et al. (2015). Genome-wide binding and
mechanistic analyses of Smchd1-mediated epigenetic regulation. Proc. Natl.
Acad. Sci. USA 112, E3535–E3544.
Cifuentes-Rojas, C., Hernandez, A.J., Sarma, K., and Lee, J.T. (2014).
Regulatory interactions between RNA and polycomb repressive complex 2.
Mol. Cell 55, 171–185.
Conrad, T., Albrecht, A.S., de Melo Costa, V.R., Sauer, S., Meierhofer, D., and
Ørom, U.A. (2016). Serial interactome capture of the human cell nucleus. Nat.
Commun. 7, 11212.
Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification
rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372.
Molecular Cell 81, 1–16, July 15, 2021 13
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
D’Orso, I., and Frankel, A.D. (2010). RNA-mediated displacement of an inhibitory snRNP complex activates transcription elongation. Nat. Struct. Mol. Biol.
17, 815–821.
Hooper, M., Hardy, K., Handyside, A., Hunter, S., and Monk, M. (1987). HPRTdeficient (Lesch-Nyhan) mouse embryos derived from germline colonization
by cultured cells. Nature 326, 292–295.
Davidovic, L., Bechara, E., Gravel, M., Jaglin, X.H., Tremblay, S., Sik, A.,
Bardoni, B., and Khandjian, E.W. (2006). The nuclear microspherule protein
58 is a novel RNA-binding protein that interacts with fragile X mental retardation protein in polyribosomal mRNPs from neurons. Hum. Mol. Genet. 15,
1525–1538.
Hosogane, M., Funayama, R., Shirota, M., and Nakayama, K. (2016). Lack of
Transcription Triggers H3K27me3 Accumulation in the Gene Body. Cell Rep.
16, 696–706.
Davidovich, C., Zheng, L., Goodrich, K.J., and Cech, T.R. (2013). Promiscuous
RNA binding by Polycomb repressive complex 2. Nat. Struct. Mol. Biol. 20,
1250–1257.
Di Ruscio, A., Ebralidze, A.K., Benoukraf, T., Amabile, G., Goff, L.A., Terragni,
J., Figueroa, M.E., De Figueiredo Pontes, L.L., Alberich-Jorda, M., Zhang, P.,
et al. (2013). DNMT1-interacting RNAs block gene-specific DNA methylation.
Nature 503, 371–376.
Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut,
P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq
aligner. Bioinformatics 29, 15–21.
Flynn, R.A., Do, B.T., Rubin, A.J., Calo, E., Lee, B., Kuchelmeister, H., Rale, M.,
Chu, C., Kool, E.T., Wysocka, J., et al. (2016). 7SK-BAF axis controls pervasive
transcription at enhancers. Nat. Struct. Mol. Biol. 23, 231–238.
Fong, Y.W., and Zhou, Q. (2001). Stimulatory effect of splicing factors on transcriptional elongation. Nature 414, 929–933.
Hendrickson, D.G., Kelley, D.R., Tenen, D., Bernstein, B., and Rinn, J.L. (2016).
Widespread RNA binding by chromatin-associated proteins. Genome Biol.
17, 28.
Garber, M.E., Wei, P., KewalRamani, V.N., Mayall, T.P., Herrmann, C.H., Rice,
A.P., Littman, D.R., and Jones, K.A. (1998). The interaction between HIV-1 Tat
and human cyclin T1 requires zinc and a critical cysteine residue that is not
conserved in the murine CycT1 protein. Genes Dev. 12, 3512–3527.
Garland, W., Comet, I., Wu, M., Radzisheuskaya, A., Rib, L., Vitting-Seerup, K.,
Lloret-Llinares, M., Sandelin, A., Helin, K., and Jensen, T.H. (2019). A
Functional Link between Nuclear RNA Decay and Transcriptional Control
Mediated by the Polycomb Repressive Complex 2. Cell Rep. 29, 1800–
1811.e6.
Giurgiu, M., Reinhard, J., Brauner, B., Dunger-Kaltenbach, I., Fobo, G.,
Frishman, G., Montrone, C., and Ruepp, A. (2019). CORUM: the comprehensive resource of mammalian protein complexes-2019. Nucleic Acids Res. 47
(D1), D559–D563.
Han, P., Li, W., Lin, C.H., Yang, J., Shang, C., Nuernberg, S.T., Jin, K.K., Xu,
W., Lin, C.Y., Lin, C.J., et al. (2014). A long noncoding RNA protects the heart
from pathological hypertrophy. Nature 514, 102–106.
Hansen, A.S., Hsieh, T.S., Cattoglio, C., Pustova, I., Saldaña-Meyer, R.,
Reinberg, D., Darzacq, X., and Tjian, R. (2019). Distinct Classes of
Chromatin Loops Revealed by Deletion of an RNA-Binding Region in CTCF.
Mol. Cell 76, 395–411.e13.
He, C., Sidoli, S., Warneford-Thomson, R., Tatomer, D.C., Wilusz, J.E., Garcia,
B.A., and Bonasio, R. (2016). High-Resolution Mapping of RNA-Binding
Regions in the Nuclear Proteome of Embryonic Stem Cells. Mol. Cell 64,
416–430.
Heinz, S., Texari, L., Hayes, M.G.B., Urbanowski, M., Chang, M.W., Givarkes,
N., Rialdi, A., White, K.M., Albrecht, R.A., Pache, L., et al. (2018). Transcription
Elongation Can Affect Genome 3D Structure. Cell 174, 1522–1536.e22.
Herzel, L., Ottoz, D.S.M., Alpert, T., and Neugebauer, K.M. (2017). Splicing and
transcription touch base: co-transcriptional spliceosome assembly and function. Nat. Rev. Mol. Cell Biol. 18, 637–650.
Herzog, V.A., Lempradl, A., Trupke, J., Okulski, H., Altmutter, C., Ruge, F.,
Boidol, B., Kubicek, S., Schmauss, G., Aumayr, K., et al. (2014). A strand-specific switch in noncoding transcription switches the function of a Polycomb/
Trithorax response element. Nat. Genet. 46, 973–981.
Hnisz, D., Shrinivas, K., Young, R.A., Chakraborty, A.K., and Sharp, P.A.
(2017). A Phase Separation Model for Transcriptional Control. Cell 169, 13–23.
14 Molecular Cell 81, 1–16, July 15, 2021
Hu, Y.W., Guo, F.X., Xu, Y.J., Li, P., Lu, Z.F., McVey, D.G., Zheng, L., Wang, Q.,
Ye, J.H., Kang, C.M., et al. (2019). Long noncoding RNA NEXN-AS1 mitigates
atherosclerosis by regulating the actin-binding protein NEXN. J. Clin. Invest.
129, 1115–1128.
Huppertz, I., Attig, J., D’Ambrogio, A., Easton, L.E., Sibley, C.R., Sugimoto, Y.,
Tajnik, M., König, J., and Ule, J. (2014). iCLIP: protein-RNA interactions at
nucleotide resolution. Methods 65, 274–287.
Jégu, T., Blum, R., Cochrane, J.C., Yang, L., Wang, C.Y., Gilles, M.E.,
Colognori, D., Szanto, A., Marr, S.K., Kingston, R.E., and Lee, J.T. (2019).
Xist RNA antagonizes the SWI/SNF chromatin remodeler BRG1 on the inactive
X chromosome. Nat. Struct. Mol. Biol. 26, 96–109.
Jeon, Y., and Lee, J.T. (2011). YY1 tethers Xist RNA to the inactive X nucleation
center. Cell 146, 119–133.
Ji, X., Zhou, Y., Pandit, S., Huang, J., Li, H., Lin, C.Y., Xiao, R., Burge, C.B., and
Fu, X.D. (2013). SR proteins collaborate with 7SK and promoter-associated
nascent RNA to release paused polymerase. Cell 153, 855–868.
Kammers, K., Cole, R.N., Tiengwe, C., and Ruczinski, I. (2015). Detecting
Significant Changes in Protein Abundance. EuPA Open Proteom. 7, 11–19.
Kaneko, S., Son, J., Shen, S.S., Reinberg, D., and Bonasio, R. (2013). PRC2
binds active promoters and contacts nascent RNAs in embryonic stem cells.
Nat. Struct. Mol. Biol. 20, 1258–1264.
Kaneko, S., Son, J., Bonasio, R., Shen, S.S., and Reinberg, D. (2014). Nascent
RNA interaction keeps PRC2 activity poised and in check. Genes Dev. 28,
1983–1988.
Kanhere, A., Viiri, K., Araújo, C.C., Rasaiyaah, J., Bouwman, R.D., Whyte,
W.A., Pereira, C.F., Brookes, E., Walker, K., Bell, G.W., et al. (2010). Short
RNAs are transcribed from repressed polycomb target genes and interact
with polycomb repressive complex-2. Mol. Cell 38, 675–688.
Katz, Y., Wang, E.T., Airoldi, E.M., and Burge, C.B. (2010). Analysis and design
of RNA sequencing experiments for identifying isoform regulation. Nat.
Methods 7, 1009–1015.
Koga, M., Hayashi, M., and Kaida, D. (2015). Splicing inhibition decreases
phosphorylation level of Ser2 in Pol II CTD. Nucleic Acids Res. 43, 8258–8267.
König, J., Zarnack, K., Rot, G., Curk, T., Kayikci, M., Zupan, B., Turner, D.J.,
Luscombe, N.M., and Ule, J. (2010). iCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution. Nat. Struct. Mol. Biol. 17,
909–915.
Kung, J.T., Kesner, B., An, J.Y., Ahn, J.Y., Cifuentes-Rojas, C., Colognori, D.,
Jeon, Y., Szanto, A., del Rosario, B.C., Pinter, S.F., et al. (2015). Locus-specific
targeting to the X chromosome revealed by the RNA interactome of CTCF.
Mol. Cell 57, 361–375.
Kwon, S.C., Yi, H., Eichelbaum, K., Föhr, S., Fischer, B., You, K.T., Castello, A.,
Krijgsveld, J., Hentze, M.W., and Kim, V.N. (2013). The RNA-binding protein
repertoire of embryonic stem cells. Nat. Struct. Mol. Biol. 20, 1122–1130.
Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with
Bowtie 2. Nat. Methods 9, 357–359.
Li, W., Notani, D., Ma, Q., Tanasa, B., Nunez, E., Chen, A.Y., Merkurjev, D.,
Zhang, J., Ohgi, K., Song, X., et al. (2013). Functional roles of enhancer
RNAs for oestrogen-dependent transcriptional activation. Nature 498,
516–520.
Li, L., Lyu, X., Hou, C., Takenaka, N., Nguyen, H.Q., Ong, C.T., Cubeñas-Potts,
C., Hu, M., Lei, E.P., Bosco, G., et al. (2015). Widespread rearrangement of 3D
chromatin organization underlies polycomb-mediated stress-induced
silencing. Mol. Cell 58, 216–231.
Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general
purpose program for assigning sequence reads to genomic features.
Bioinformatics 30, 923–930.
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
Lin, S., Coutinho-Mansfield, G., Wang, D., Pandit, S., and Fu, X.D. (2008). The
splicing factor SC35 has an active role in transcriptional elongation. Nat.
Struct. Mol. Biol. 15, 819–826.
web server for deep-sequencing data analysis. Nucleic Acids Res. 44 (W1),
W160–W165.
Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold
change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550.
Raudvere, U., Kolberg, L., Kuzmin, I., Arak, T., Adler, P., Peterson, H., and Vilo,
J. (2019). g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 47 (W1), W191–W198.
€we, C., Foster, B.M., Nguyen, N.V., Bartke, T., and
Makowski, M.M., Gra
Vermeulen, M. (2018). Global profiling of protein-DNA and protein-nucleosome
binding affinities using quantitative mass spectrometry. Nat. Commun.
9, 1653.
Reynolds, N., Salmon-Divon, M., Dvinge, H., Hynes-Allen, A., Balasooriya, G.,
Leaford, D., Behrens, A., Bertone, P., and Hendrich, B. (2012). NuRD-mediated deacetylation of H3K27 facilitates recruitment of Polycomb Repressive
Complex 2 to direct gene repression. EMBO J. 31, 593–605.
Mayer, C., Schmitz, K.M., Li, J., Grummt, I., and Santoro, R. (2006). Intergenic
transcripts regulate the epigenetic state of rRNA genes. Mol. Cell 22, 351–361.
Richter, S., Ping, Y.H., and Rana, T.M. (2002). TAR RNA loop: a scaffold for the
assembly of a regulatory switch in HIV replication. Proc. Natl. Acad. Sci. USA
99, 7928–7933.
McNamara, R.P., Reeder, J.E., McMillan, E.A., Bacon, C.W., McCann, J.L.,
and D’Orso, I. (2016). KAP1 Recruitment of the 7SK snRNP Complex to
Promoters Enables Transcription Elongation by RNA Polymerase II. Mol. Cell
61, 39–53.
Michels, A.A., Nguyen, V.T., Fraldi, A., Labas, V., Edwards, M., Bonnet, F.,
Lania, L., and Bensaude, O. (2003). MAQ1 and 7SK RNA interact with
CDK9/cyclin T complexes in a transcription-dependent manner. Mol. Cell.
Biol. 23, 4859–4869.
Mondal, T., Rasmussen, M., Pandey, G.K., Isaksson, A., and Kanduri, C.
(2010). Characterization of the RNA content of chromatin. Genome Res. 20,
899–907.
Monte, E., Chen, H., Kolmakova, M., Parvatiyar, M., Vondriska, T.M., and
Franklin, S. (2012). Quantitative analysis of chromatin proteomes in disease.
J. Vis. Exp. 70, 4294.
Mullari, M., Lyon, D., Jensen, L.J., and Nielsen, M.L. (2017). Specifying RNABinding Regions in Proteins by Peptide Cross-Linking and Affinity Purification.
J. Proteome Res. 16, 2762–2772.
Nickerson, J.A., Krochmalnic, G., Wan, K.M., and Penman, S. (1989).
Chromatin architecture and nuclear RNA. Proc. Natl. Acad. Sci. USA 86,
177–181.
Nozawa, R.S., and Gilbert, N. (2019). RNA: Nuclear Glue for Folding the
Genome. Trends Cell Biol. 29, 201–211.
Nozawa, R.S., Boteva, L., Soares, D.C., Naughton, C., Dun, A.R., Buckle, A.,
Ramsahoye, B., Bruton, P.C., Saleeb, R.S., Arnedo, M., et al. (2017). SAF-A
Regulates Interphase Chromosome Structure through Oligomerization with
Chromatin-Associated RNAs. Cell 169, 1214–1227.e18.
Riising, E.M., Comet, I., Leblanc, B., Wu, X., Johansen, J.V., and Helin, K.
(2014). Gene silencing triggers polycomb repressive complex 2 recruitment
to CpG islands genome wide. Mol. Cell 55, 347–360.
Rinn, J.L., and Chang, H.Y. (2012). Genome regulation by long noncoding
RNAs. Annu. Rev. Biochem. 81, 145–166.
Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K.
(2015). limma powers differential expression analyses for RNA-sequencing
and microarray studies. Nucleic Acids Res. 43, e47.
Rivers, C., Idris, J., Scott, H., Rogers, M., Lee, Y.B., Gaunt, J., Phylactou, L.,
Curk, T., Campbell, C., Ule, J., et al. (2015). iCLIP identifies novel roles for
SAFB1 in regulating RNA processing and neuronal function. BMC Biol.
13, 111.
Robinson, M.D., and Oshlack, A. (2010). A scaling normalization method for
differential expression analysis of RNA-seq data. Genome Biol. 11, R25.
Saldaña-Meyer, R., González-Buendı́a, E., Guerrero, G., Narendra, V.,
Bonasio, R., Recillas-Targa, F., and Reinberg, D. (2014). CTCF regulates the
human p53 gene through direct interaction with its natural antisense transcript,
Wrap53. Genes Dev. 28, 723–734.
Saldaña-Meyer, R., Rodriguez-Hernaez, J., Escobar, T., Nishana, M., JácomeLópez, K., Nora, E.P., Bruneau, B.G., Tsirigos, A., Furlan-Magaril, M., Skok, J.,
and Reinberg, D. (2019). RNA Interactions Are Essential for CTCF-Mediated
Genome Organization. Mol. Cell 76, 412–422.e5.
Savell, K.E., Gallus, N.V., Simon, R.C., Brown, J.A., Revanna, J.S., Osborn,
M.K., Song, E.Y., O’Malley, J.J., Stackhouse, C.T., Norvil, A., et al. (2016).
Extra-coding RNAs regulate neuronal DNA methylation dynamics. Nat.
Commun. 7, 12091.
Pan, H., Jin, M., Ghadiyaram, A., Kaur, P., Miller, H.E., Ta, H.M., Liu, M., Fan,
Y., Mahn, C., Gorthi, A., et al. (2020). Cohesin SA1 and SA2 are RNA binding
proteins that localize to RNA containing regions on DNA. Nucleic Acids Res.
48, 5639–5655.
Sedore, S.C., Byers, S.A., Biglione, S., Price, J.P., Maury, W.J., and Price, D.H.
(2007). Manipulation of P-TEFb control machinery by HIV: recruitment of PTEFb from the large form by Tat and binding of HEXIM1 to TAR. Nucleic
Acids Res. 35, 4347–4358.
Perez-Perri, J.I., Rogell, B., Schwarzl, T., Stein, F., Zhou, Y., Rettel, M., Brosig,
A., and Hentze, M.W. (2018). Discovery of RNA-binding proteins and characterization of their dynamic responses by enhanced RNA interactome capture.
Nat. Commun. 9, 4408.
Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin,
N., Schwikowski, B., and Ideker, T. (2003). Cytoscape: a software environment
for integrated models of biomolecular interaction networks. Genome Res. 13,
2498–2504.
Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S.,
Kundu, D.J., Inuganti, A., Griss, J., Mayer, G., Eisenacher, M., et al. (2019). The
PRIDE database and related tools and resources in 2019: improving support
for quantification data. Nucleic Acids Res. 47 (D1), D442–D450.
Sigova, A.A., Abraham, B.J., Ji, X., Molinie, B., Hannett, N.M., Guo, Y.E., Jangi,
M., Giallourakis, C.C., Sharp, P.A., and Young, R.A. (2015). Transcription factor trapping by RNA in gene regulatory elements. Science 350, 978–981.
Prensner, J.R., Iyer, M.K., Sahu, A., Asangani, I.A., Cao, Q., Patel, L., Vergara,
I.A., Davicioni, E., Erho, N., Ghadessi, M., et al. (2013). The long noncoding
RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the
SWI/SNF complex. Nat. Genet. 45, 1392–1398.
Quaresma, A.J.C., Bugai, A., and Barboric, M. (2016). Cracking the control of
RNA polymerase II elongation by 7SK snRNP and P-TEFb. Nucleic Acids Res.
44, 7527–7539.
Rahnamoun, H., Lee, J., Sun, Z., Lu, H., Ramsey, K.M., Komives, E.A., and
Lauberth, S.M. (2018). RNAs interact with BRD4 to promote enhanced chromatin engagement and transcription activation. Nat. Struct. Mol. Biol. 25,
687–697.
€ning, B., Bhardwaj, V., Kilpert, F., Richter, A.S.,
Ramı́rez, F., Ryan, D.P., Gru
€ndar, F., and Manke, T. (2016). deepTools2: a next generation
Heyne, S., Du
Skalska, L., Beltran-Nebot, M., Ule, J., and Jenner, R.G. (2017). Regulatory
feedback from nascent RNA to chromatin and transcription. Nat. Rev. Mol.
Cell Biol. 18, 331–337.
Smedley, D., Haider, S., Ballester, B., Holland, R., London, D., Thorisson, G.,
and Kasprzyk, A. (2009). BioMart–biological queries made easy. BMC
Genomics 10, 22.
St Laurent, G., Shtokalo, D., Tackett, M.R., Yang, Z., Eremina, T., Wahlestedt,
C., Urcuqui-Inchima, S., Seilheimer, B., McCaffrey, T.A., and Kapranov, P.
(2012). Intronic RNAs constitute the major fraction of the non-coding RNA in
mammalian cells. BMC Genomics 13, 504.
Stock, J.K., Giadrossi, S., Casanova, M., Brookes, E., Vidal, M., Koseki, H.,
Brockdorff, N., Fisher, A.G., and Pombo, A. (2007). Ring1-mediated ubiquitination of H2A restrains poised RNA polymerase II at bivalent genes in mouse ES
cells. Nat. Cell Biol. 9, 1428–1435.
Molecular Cell 81, 1–16, July 15, 2021 15
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
Studniarek, C., Tellier, M., Martin, P.G.P., Murphy, S., Kiss, T., and Egloff, S.
(2021). The 7SK/P-TEFb snRNP controls ultraviolet radiation-induced transcriptional reprogramming. Cell Rep. 35, 108965.
Wang, X., Paucek, R.D., Gooding, A.R., Brown, Z.Z., Ge, E.J., Muir, T.W., and
Cech, T.R. (2017b). Molecular analysis of PRC2 recruitment to DNA in chromatin and its inhibition by RNA. Nat. Struct. Mol. Biol. 24, 1028–1038.
Szklarczyk, D., Gable, A.L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J.,
Simonovic, M., Doncheva, N.T., Morris, J.H., Bork, P., et al. (2019). STRING
v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic
Acids Res. 47 (D1), D607–D613.
Wei, P., Garber, M.E., Fang, S.M., Fischer, W.H., and Jones, K.A. (1998). A
novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92, 451–462.
Tie, C.H., Fernandes, L., Conde, L., Robbez-Masson, L., Sumner, R.P.,
Peacock, T., Rodriguez-Plata, M.T., Mickute, G., Gifford, R., Towers, G.J.,
et al. (2018). KAP1 regulates endogenous retroviruses in adult human cells
and contributes to innate immune control. EMBO Rep. 19, e45000.
Trendel, J., Schwarzl, T., Horos, R., Prakash, A., Bateman, A., Hentze, M.W.,
and Krijgsveld, J. (2019). The Human RNA-Binding Proteome and Its
Dynamics during Translational Arrest. Cell 176, 391–403.e19.
Tsai, P.F., Dell’Orso, S., Rodriguez, J., Vivanco, K.O., Ko, K.D., Jiang, K., Juan,
A.H., Sarshad, A.A., Vian, L., Tran, M., et al. (2018). A Muscle-Specific
Enhancer RNA Mediates Cohesin Recruitment and Regulates Transcription
In trans. Mol. Cell 71, 129–141.e8.
UniProt Consortium (2019). UniProt: a worldwide hub of protein knowledge.
Nucleic Acids Res. 47 (D1), D506–D515.
Werner, M.S., and Ruthenburg, A.J. (2015). Nuclear Fractionation Reveals
Thousands of Chromatin-Tethered Noncoding RNAs Adjacent to Active
Genes. Cell Rep. 12, 1089–1098.
Wickham, H. (2016). ggplot2: Elegant Graphics for Data Analysis (Springer).
Xue, Y., Pradhan, S.K., Sun, F., Chronis, C., Tran, N., Su, T., Van, C., Vashisht,
A., Wohlschlegel, J., Peterson, C.L., et al. (2017). Mot1, Ino80C, and NC2
Function Coordinately to Regulate Pervasive Transcription in Yeast and
Mammals. Mol. Cell 67, 594–607.e4.
Yik, J.H., Chen, R., Nishimura, R., Jennings, J.L., Link, A.J., and Zhou, Q.
(2003). Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II
transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Mol.
Cell 12, 971–982.
Zhang, Q., McKenzie, N.J., Warneford-Thomson, R., Gail, E.H., Flanigan, S.F.,
Owen, B.M., Lauman, R., Levina, V., Garcia, B.A., Schittenhelm, R.B., et al.
(2019). RNA exploits an exposed regulatory site to inhibit the enzymatic activity
of PRC2. Nat. Struct. Mol. Biol. 26, 237–247.
Wang, K.C., Yang, Y.W., Liu, B., Sanyal, A., Corces-Zimmerman, R., Chen, Y.,
Lajoie, B.R., Protacio, A., Flynn, R.A., Gupta, R.A., et al. (2011). A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression.
Nature 472, 120–124.
Zhao, L., Guo, H., Zhou, B., Feng, J., Li, Y., Han, T., Liu, L., Li, L., Zhang, S., Liu,
Y., et al. (2016). Long non-coding RNA SNHG5 suppresses gastric cancer progression by trapping MTA2 in the cytosol. Oncogene 35, 5770–5780.
Wang, X., Goodrich, K.J., Gooding, A.R., Naeem, H., Archer, S., Paucek, R.D.,
Youmans, D.T., Cech, T.R., and Davidovich, C. (2017a). Targeting of Polycomb
Repressive Complex 2 to RNA by Short Repeats of Consecutive Guanines.
Mol. Cell 65, 1056–1067.e5.
Zoabi, M., Nadar-Ponniah, P.T., Khoury-Haddad, H., Usaj, M., Budowski-Tal,
I., Haran, T., Henn, A., Mandel-Gutfreund, Y., and Ayoub, N. (2014). RNAdependent chromatin localization of KDM4D lysine demethylase promotes
H3K9me3 demethylation. Nucleic Acids Res. 42, 13026–13038.
16 Molecular Cell 81, 1–16, July 15, 2021
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE
SOURCE
IDENTIFIER
DNMT3A
Abcam
Cat# ab285;, RRID:AB_303355
TRRAP
Abcam
Cat# ab73546; RRID:AB_10672042
LMNA
Abcam
Cat# ab26300; RRID:AB_775965
HMGN1
Bethyl Laboratories
Cat# A302-363A; RRID:AB_1907246
UTF1
Abcam
Cat# ab24273; RRID:AB_778767
CDK9
Abcam
Cat# ab6544; RRID:AB_305557
Beta-Tubulin
Abcam
Cat# ab6046; RRID:AB_2210370
Beta-Actin
Cell Signaling Technology
Cat# 4967; RRID:AB_330288
RUVBL2
Abcam
Cat# ab36569; RRID:AB_2301439
SF3A3
Bethyl Laboratories
Cat# A302-506A; RRID:AB_1966116
ZFP57
Abcam
Cat# ab45341; RRID:AB_946192
FUS
Novus Biologicals
Cat# NB 100-565; RRID:AB_523761
ILF3
Abcam
Cat# ab92355; RRID:AB_2049804
CyclinT1
Abcam
Cat# ab184703; RRID:AB_2814653
UBTF
Santa Cruz
Cat# sc-13125; RRID:AB_671403
KAP1/TRIM28
Abcam
Cat# ab3831; RRID:AB_304099
SUZ12
Santa Cruz
Cat# sc-46264; RRID:AB_2196857
HNRNPU
Abcam
Cat# ab10297; RRID:AB_297037
EHMT1
Abcam
Cat# ab41969; RRID:AB_732115
STAG1
Abcam
Cat# ab4457; RRID:AB_2286589
STAG2
Abcam
Cat# ab4463; RRID:AB_304471
SMARCC1
Abcam
Cat# ab172638
BRD4
Santa Cruz
Cat# sc-48772; RRID:AB_2065729
INO80
ProteinTech
Cat# 18810-1-AP; RRID:AB_10598463
CHD1
Cell Signaling Technology
Cat# 4351; RRID:AB_11179073
CHD4
Abcam
Cat# ab70469; RRID:AB_2229454
CHD8
Bethyl Laboratories
Cat# A301-224A; RRID:AB_890578
P300
Santa Cruz
Cat# SC-585; RRID:AB_2231120
KDM2A
Bethyl Laboratories
Cat# A301-475A; RRID:AB_999558
LEO1
Bethyl Laboratories
Cat# A300-174A; RRID:AB_309451
MPP8
Santa Cruz
Cat# sc-398598
SMARCA5
Abcam
Cat# ab3749; RRID:AB_2191856
INST11
Bethyl Laboratories
Cat# A301-274A; RRID:AB_937779
Pol II S2P
Abcam
Cat# ab5095; RRID:AB_304749
Pol II S5P
Millipore
Cat# 05-623; RRID:AB_309852
Total Pol II
Santa Cruz
Cat# sc-899; RRID:AB_632359
Histone H3
Abcam
Cat# ab1791; RRID:AB_302613
LARP7
Bethyl Laboratories
Cat# A303-723A; RRID:AB_11205813
CDK9 (for CLIP/iCLIP)
Santa Cruz
Cat# sc-484; RRID:AB_2275986
CyclinT1 (for CLIP & coIP)
Abcam
Cat# ab238940
Non-specific IgG
Abcam
Cat# ab46540; RRID:AB_2614925
FLAG antibody
Sigma
Cat# F3165; RRID:AB_259529
gH2A.X (Ser139) (clone JBW301)
Sigma
Cat# 05-636-I; RRID:AB_2755003
Antibodies
(Continued on next page)
Molecular Cell 81, 1–16.e1–e10, July 15, 2021 e1
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
Continued
REAGENT or RESOURCE
SOURCE
IDENTIFIER
N/A
N/A
Cat# T3652
Bacterial and virus strains
E. coli BL21
Chemicals, peptides, and recombinant proteins
Triptolide
Sigma
Flavopiridol hydrochloride hydrate
Sigma
Cat# F3055
Pladienolide B
Santa Cruz
Cat# sc-391691
SUPERase.In
Invitrogen
Cat# AM2694
RNaseA
Sigma
Cat# R6513
Cat# E1014
Benzonase
Sigma
RNaseOUT
Invitrogen
Cat# 1077019
Yeast tRNA
Invitrogen
Cat# AM7119
Iodoacetamide
Sigma
Cat# I1149
Trypsin
Promega
Cat# V5113
Streptavidin Dynabead T1
Invitrogen
Cat# 65601
DNase Turbo
Ambion
Cat# AM2238
RNase I
Ambion
Cat# AM2294
Dynabeads protein G
Invitrogen
Cat# 10003D
SYBR Green I
Invitrogen
Cat# S7585
TRIsure
Bioline
Cat# BIO-38033
TRI Reagent
Sigma
Cat# T3934
SuperScript III Reverse Transcriptase
Invitrogen
Cat# 18080044
ImProm-II Reverse Transcription System
Promega
Cat# A3800
SN-38
Sigma
Cat# H0165
Viability Dye eF780
Invitrogen
Cat# 65-0865-14
Doxorubicin
Sigma
Cat# D1515
Pierce BCA
Thermo Scientific
Cat# 23225
KAPA Universal Library Quantification kit
Roche
Cat# KK4824
Amaxa Mouse ES Cell Nucleofector kit
Lonza
Cat# VPH-1001
QuantiTect SYBR Green PCR kit
QIAGEN
Cat# 204143
Vybrant FAM Caspase-3 and 7 assay kit
Invitrogen
Cat# V35118
Critical commercial assays
Deposited data
SILAC proteomics data
This paper
PRIDE: PXD018706
Label-free proteomics data
This paper
PRIDE: PXD018641
iCLIP data
This paper
GEO: GSE150677
RNA-seq data
This paper
GEO: GSE150677
Raw image files
This paper
Mendeley Data: https://doi.org/
10.17632/67dcgtbks5.12
Experimental models: Cell lines
E14 ESC
Hooper et al., 1987
RRID:CVCL_C320
WT HAP1
Studniarek et al., 2021
RRID:CVCL_Y019
7SK KO HAP1
Studniarek et al., 2021
N/A
WT HEK293T
Tie et al., 2018
RRID:CVCL_0063
KAP1 KO HEK293T
Tie et al., 2018
N/A
7SK F 50 -AGAACGTAGGGTAGTCAAGC-30
Kanhere et al., 2010
N/A
7SK R 50 -AGAAAGGCAGACTGCCACAT-30
Kanhere et al., 2010
N/A
Actb F 50 -TCTTTGCAGCTCCTTCGTTG-30
Stock et al., 2007
N/A
Oligonucleotides
(Continued on next page)
e2 Molecular Cell 81, 1–16.e1–e10, July 15, 2021
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
Continued
REAGENT or RESOURCE
SOURCE
IDENTIFIER
Actb R 5 ACGATGGAGGGGAATACAGC-30
Stock et al., 2007
N/A
5S rRNA F 50 AAGCCTACAGCACCCGGTAT-30
Kanhere et al., 2010
N/A
5S rRNA R 50 GATCTCGGAAGCTAAGCAGG-30
Kanhere et al., 2010
N/A
7SK ASO
Flynn et al., 2016
N/A
Scrambled ASO
Flynn et al., 2016
N/A
MaxQuant v1.6.0.13
Cox and Mann, 2008
RRID:SCR_014485
TMM
Robinson and Oshlack, 2010
N/A
Limma
Kammers et al., 2015; Ritchie et al., 2015
RRID:SCR_010943
g:Profiler2 v1.2
Raudvere et al., 2019
RRID:SCR_018190
Ensembl BioMart
Smedley et al., 2009
RRID:SCR_010714
HGNC multi-symbol checker
https://www.genenames.org/tools/multisymbol-checker/
RRID:SCR_002827
CORUM v3.0
Giurgiu et al., 2019
RRID:SCR_002254
Cytoscape v3.5
Shannon et al., 2003
RRID:SCR_003032
STRING v11
Szklarczyk et al., 2019
RRID:SCR_005223
iCount
König et al., 2010 https://github.com/
tomazc/iCount
RRID:SCR_016712
bowtie2 version 2.1.0
Langmead and Salzberg, 2012
RRID:SCR_016368
MISO
Katz et al., 2010
RRID:SCR_003124
STAR version 2.7.3a
Dobin et al., 2013
RRID:SCR_004463
DeepTools version 3.0.2
Ramı́rez et al., 2016
RRID:SCR_016366
featureCounts version 5.25
Liao et al., 2014
RRID:SCR_012919
DEseq2
Love et al., 2014
RRID:SCR_015687
ggplot2
Wickham, 2016
RRID:SCR_014601
AmiGO 2
http://amigo.geneontology.org/amigo
RRID:SCR_002143
0
Software and algorithms
RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Richard G.
Jenner (r.jenner@ucl.ac.uk).
Materials availability
This study did not generate new unique reagents.
Data and code availability
The SILAC and label-free mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the
PRIDE (Perez-Riverol et al., 2019) partner repository with the dataset identifiers PRIDE: PXD018706 and PRIDE: PXD018641, respectively. iCLIP and RNA-seq data have been deposited in the Gene Expression Omnibus (GEO) with accession code GEO: GSE150677.
Raw immunoblotting and autoradiogram images have been deposited in Mendeley Data: https://doi.org/10.17632/67dcgtbks5.12.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
All cells were cultured at 37 C in 5% CO2. Cell lines were not authenticated. Mouse E14 ESC (male) (Hooper et al., 1987) were maintained on 0.1% gelatin in KO-DMEM, 10% FCS, 5% knockout serum replacement, non-essential amino acids, L-glutamine, 2-mercaptoethanol, penicillin-streptomycin and 1000 U/ml leukemia inhibitory factor (Amsbio #AMS-263-100). For Pol II inhibition and
Molecular Cell 81, 1–16.e1–e10, July 15, 2021 e3
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
nucleosome IP mass spectrometry studies, media was supplemented with 100 mg/l lysine K8 CNLM-291-H, 100 mg/l arginine R10
CNLM-539-H or 100 mg/l light amino acids (K0 and R0) (ThermoFisher #89989 #89987), and 100 mg/l proline. Cells were maintained
for 6 passages (14 doublings) to ensure full amino acid incorporation and were assayed for alkaline phosphatase activity (ThermoFisher #A14353). WT and 7SK KO HAP1 cells (haploid male) (kind gift from Sylvain Egloff; Studniarek et al., 2021) were maintained in
Iscove’s Modified Dulbecco’s Medium (IMDM) with 10% FCS and penicillin/streptomycin. WT and KAP KO HEK293T cells (female;
kind gift from Helen Rowe; Tie et al., 2018) were maintained in DMEM, 10% FCS and penicillin-streptomycin. ESC, HAP1 and
HEK293T cells were incubated at 37 C and treated with triptolide (10 mM, Sigma T3652), flavopiridol (10 mM, Sigma F3055), or an
equivalent volume of DMSO, for the times indicated. For reversal of transcriptional inhibition induced by flavopiridol, after 3 hr of treatment, ESC were washed twice with warm medium and incubated for a further 3 hr. ESC were treated with 1 mM pladienolide B (Santa
Cruz sc-391691) or an equal volume of DMSO for 6 hr.
METHOD DETAILS
Experiments were not performed blinded. Samples were not randomized.
Cell fractionation for proteomics experiments
For the Pol II inhibition experiments, heavy and light labeled ESC were treated with triptolide and flavopiridol as described above. For the
RNA degradation experiments, RNaseA treatment was performed as described (Beltran et al., 2016). ESC were trypsinized, washed
twice with PBS, permeabilized with 0.05% Tween-20 in PBS for 10 min on ice, washed once, resuspended with PBS and mock-treated
with 1 U/ml SUPERase.In (Invitrogen AM2694) or treated with 1 mg/ml RNaseA (Sigma R6513) for 30 min at RT. Chromatin fractions were
then purified as described (Monte et al., 2012). Cells were then centrifuged at 1200 rpm, washed twice with PBS, and re-suspended in a
hypotonic lysis buffer, (10 mM Tris pH 7.5, 15 mM NaCl, 0.15% v/v NP-40) with protease and phosphatase inhibitors (10 mM sodium
butyrate, 0.1 mM PMSF, 0.2 mM Na3VO4, 0.1 mM NaF, Complete protease inhibitor and 1 U/ ml Superase.In) and incubated on ice for
5 min. Cells were then centrifuged at 4,000 rpm for 5 min at 4 C and the cytoplasmic supernatant harvested. The nuclear pellet was resuspended in hypotonic lysis buffer and layered gently onto a sucrose cushion (24% sucrose (w/v), 10 mM Tris pH 7.5, 15 mM NaCl with
protease/phosphatase inhibitors and 1 U/ml Superase.In), centrifuged for 10 min at 5,000 rpm and washed with PBS. Isolated nuclei
were then resuspended in 20 mM HEPES (pH 7.6), 7.5 mM MgCl2, 30 mM NaCl, 1 M urea, 1% NP-40 with protease/phosphatase inhibitor and 1 U/ml Superase.In and incubated for 10 min on ice to extract soluble proteins. Samples were then centrifuged at 13,000 rpm
for 10 min to pellet the insoluble chromatin and the soluble nucleoplasmic fraction removed. The chromatin pellet was washed with PBS
and proteins extracted in 50 mM Tris (pH 8), 1 mM EDTA, 0.05% SDS with protease/phosphatase inhibitors and treated with 250 units of
benzonase (Sigma E1014) in the presence of 2 mM MgCl2 for 1 hr. Buffer was then added to give a final concentration of 50 mM Tris (pH
8), 10 mM EDTA, 1% SDS with protease/phosphatase inhibitors and incubated at RT for 10 min. Insoluble material was removed by
centrifugation at 13,000 g for 15 mins at 4 C and the supernatant harvested.
Nucleosome affinity purification for proteomics
Heavy and light labeled ESC were trypsinised, collected by centrifugation and washed with PBS. Cell pellets were resuspended in 10
volumes of hypertonic buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT and Complete protease inhibitor) for
10 mins on ice. Cells were recovered by centrifugation at 1500 g for 5 mins and the pellet resuspended in 3 volumes of hypertonic
buffer supplemented with 0.1% IGEPAL CA-360 and incubated for 10 mins at 4 C. Nuclei were pelleted by centrifugation at 1500 g for
5 mins and resuspended in 5 mM HEPES pH 7.9, 26% glycerol, 250 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT and Complete protease inhibitor. The NaCl concentration was then slowly increased to 400 mM and nuclear extraction carried out for 1 hr at
4 C with occasional agitation. Insoluble material was removed by centrifugation (13.000rpm, 20 min at 4 C) and soluble nuclear extracts cleared using a Proteus clarification column (Generon #MSF500). Protein concentration was measured using Pierce BCA
(ThermoFisher Scientific 23225). Nuclear extracts were then treated with 1 mg/ml RNaseA (Sigma R6513) or mock treated with
PBS with 1 U/ml RNaseOUT (Invitrogen 1077019) for 30 mins at 1100 rpm at 37 C. The RNaseA treated sample was then split and
half treated with 1 U/ml RNaseOUT and half with 1 U/ml RNaseOUT and 2 mg/ml tRNA (Invitrogen AM7119). Histone octamers were
assembled into dinucleosomes by salt deposition dialysis using a biotinylated 382 bp DNA fragment containing the 601 nucleosome-positioning sequence, as described (Makowski et al., 2018). 2.5 mg of dinucleosomes were incubated with 12.5 mL of previously washed Streptavidin Dynabead T1 (Invitrogen 65601) in SNAP Buffer (20 mM HEPES pH 7.9, 150 mM NaCl, 0.2 mM EDTA
(pH 8.0), 1 mM DTT, 20% Glycerol, 0.1%, IGEPAL CA-630, plus Complete protease inhibitor) for 1 hr at 4 C. Complexes were washed
twice in SNAP buffer and then incubated with 1.2 mg of mock-treated or RNaseA-treated nuclear extract in SNAP buffer with a final
volume of 1 ml. The binding reaction was allowed to proceed for 3 hr at 4 C, beads were then washed twice in SNAP buffer and twice
in SNAP buffer without IGEPAL CA-630. Nucleosomes were resuspended in 50 ml elution buffer (100 mM Tris pH 7.5, 2 M Urea,
10 mM DTT) and incubated for 20 mins at 25 C at 1100 rpm.
SILAC
For the Pol II inhibition experiments, protein extracts were quantified by BCA. 25 mg of heavy and light labeled samples were mixed to
give a total of 50 mg protein. 25 mg of heavy or light-labeled flavopiridol or triptolide-treated samples were mixed with DMSO-treated
e4 Molecular Cell 81, 1–16.e1–e10, July 15, 2021
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
samples from the same time point labeled with the alternative amino acids. Heavy labeled samples were also mixed with the equivalent light labeled samples as controls. Heavy or light-labeled flavopiridol washout samples were mixed with alternatively-labeled 3 hr
flavopiridol, 3 hr DMSO or washout samples. Mixes were loaded onto separate lanes of a 10% NuPAGE gel (Invitrogen) and run approx. 10 mm. Each lane was manually excised, diced into 1 mm3 pieces and transferred to a single well of a flat-bottomed 96-well
plate. A Janus liquid handling robot (Perkin Elmer) was used to de-stain, reduce (10 mM dithiothreitol) and alkylate (55 mM iodoacetamide) proteins prior to overnight trypsin digest (100 ng, Pierce Trypsin Protease, MS Grade) at 37 C. The following day, peptides
were extracted using 50% acetonitrile, 1% formic acid. Peptide samples were dried by vacuum centrifugation then re-solubilised in
0.1% trifluoroacetic acid prior to mass spectrometry analysis.
For the nucleosome affinity purification experiments, equal volumes of affinity-purified proteins from the heavy or light-labeled
RNaseA-treated samples were mixed with the proteins purified from the alternatively-labeled mock-treated samples or with alternatively-labeled RNaseA treated samples as controls. Iodoacetamide (Sigma I1149) was added to a final concentration of 50 mM and
samples incubated for a further 10 mins at 25 C at 1100 rpm in the dark. Proteins were digested by addition of 0.3 mg trypsin (Promega V5113) at 25 C for 2 hr at 1100 rpm. Samples were pelleted, the supernatant collected and a second trypsinization performed
using 50 ml of elution buffer for 5 mins at 25 C. The supernatant was again collected, combined with the previous sample, and digested by incubation with 0.3 mg of trypsin overnight at 25 C and 1100 rpm. The reaction was then stopped with 0.5% TFA (Sigma),
samples desalted using C18 Stage tips and eluted in 60% acetonitrile.
A Thermo Fisher Scientific UltiMate 3000 UHPLC instrument loaded peptide samples onto a trap cartridge (Acclaim PepMap 100
C18, 300 mm inner diameter, 5 mm length, 5 mm particle size) for desalting. Peptides were transferred to an EASY-Spray analytical
column (PepMap C18, 50 mm inner diameter, 15 cm length, 2 mm particle size, 100 Å pore size) and separated using a 120-minute
gradient of increasing organic solvent (80% acetonitrile, 5% dimethyl sulfoxide) from 8 to 40%. An orbitrap Fusion Lumos Tribrid
(Thermo Fisher Scientific) mass spectrometer was operated in positive ionisation mode to acquire data. Instrument settings were:
MS1 data were acquired in the orbitrap at a resolution of 120k, 4E6 AGC target, 50 ms maximum injection time, dynamic exclusion
of 60 s, a mass range of 300-1500 m/z and profile mode data capture. MS2 data were acquired in the ion trap using a 2 m/z isolation
window, 2E4 AGC target, 300 ms maximum injection time (inject ions for all available parallelisable time ‘‘Universal Method’’), 35%
collision-induced dissociation (CID) energy, 10 ms activation time and centroid mode data capture.
Label-free quantification (LFQ)
Chromatin fractions from RNaseA-treated and mock-treated cells were collected from 4 independent experiments, loaded onto
separate wells of a NuPAGE gel (Invitrogen) and run until fully resolved. The gel was cut horizontally into five sections to facilitate
quantification by molecular weight across lanes. Bands from each lane were excised and diced into 1 mm3 pieces. Gel pieces
were washed with 50% acetonitrile and water. Proteins were reduced with 10 mM dithiothreitol in 100 mM ammonium bicarbonate
at 56 C for 45 min and alkylated with 55 mM iodoacetamide in 100 mM ammonium bicarbonate at ambient temperature for 30 mins in
the dark. Gel pieces were washed again as before. Proteins were digested with 300 ng trypsin at 37 C overnight. Peptides were extracted with 50% and 100% acetonitrile washes. Samples were evaporated to dryness at 30 C and resolubilised in 0.1% formic acid.
LC-MS/MS was performed on a Q Exactive Orbitrap Plus interfaced to a NANOSPRAY FLEX ion source and coupled to an Easy-nLC
1200 (Thermo Scientific). Thirty five percent of each sample was analyzed as 7 ml injections. Peptides were separated on a 24 cm
fused silica emitter, 75 mm diameter, packed in-house with Reprosil-Pur 200 C18-AQ, 2.4 mm resin (Dr. Maisch) using a linear gradient
from 5% to 30% acetonitrile/0.1% formic acid over 120 min at a flow rate of 250 nl/min. Peptides were ionised by electrospray ionisation using 1.8 kV applied immediately prior to the analytical column via a microtee built into the nanospray source with the ion
transfer tube heated to 320 C and the S-lens set to 60%. Precursor ions were measured in a data-dependent mode in the orbitrap
analyzer at a resolution of 70,000 and a target value of 3e6 ions. The ten most intense ions from each MS1 scan were isolated, fragmented in the HCD cell, and measured in the orbitrap at a resolution of 17,500.
Cell fractionation for validation experiments
To validate changes in chromatin association upon Pol II inhibition and RNA degradation detected by LC-MS/MS, ESC were treated
with triptolide, flavopiridol or RNaseA as described above. Cell fractionation was performed as described previously (Beltran et al.,
2016; Zoabi et al., 2014). Cells were centrifuged at 1200 rpm, washed twice with PBS and 20% of the cells separated for use as WCE.
The remaining cells were re-suspended in 1 mL of buffer A (10 mM HEPES (pH 7.9), 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10%
glycerol, 1 mM DTT with Complete protease inhibitor). Triton X-100 (0.1%) was added, and the cells were incubated for 5 min on ice.
Nuclei were collected by low-speed centrifugation (4 min, 1,300 g, 4 C). The supernatant (cytoplasmic fraction) was further clarified
by high-speed centrifugation (15 min, 20,000 g, 4 C). Nuclei were washed twice in buffer A, and then lysed in buffer B (3 mM EDTA,
0.2 mM EGTA, 1 mM DTT, Complete protease inhibitor). Insoluble chromatin was collected by centrifugation (4 min, 1,700 g, 4 C),
and the supernatant (nucleoplasm) harvested. The final chromatin pellet (insoluble chromatin fraction) was washed twice with buffer
B and proteins extracted in 50 mM Tris (pH 8), 1 mM EDTA, 0.05% SDS with Complete protease inhibitor and 250 units of benzonase
in the presence of 2 mM MgCl2 for 1 hr. Buffer was then added to give a final concentration of 50 mM Tris (pH 8), 10 mM EDTA, 1%
SDS with Complete protease inhibitor and incubated at RT for 10 min. Insoluble material was removed by centrifugation at 13,000 g
for 15 mins at 4 C and the supernatant harvested. The experiments were performed in duplicate.
Molecular Cell 81, 1–16.e1–e10, July 15, 2021 e5
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
Nucleosome affinity purification validation
Recombinant human histones were expressed in E. coli and purified as described (Makowski et al., 2018). Histone octamers were
assembled into mononucleosomes and dinucleosomes by salt deposition dialysis using biotinylated 147, 185 and 382 bp DNA fragments containing the 601 nucleosome-positioning sequence. 1.25 mg dinucleosomes pre-bound to Streptavidin Dynabead T1 or
equimolar amount of mononucleosomes were incubated with 50 mg of mock or RNaseA-treated nuclear extract in SNAP buffer
with a final volume of 250 ml. The binding reaction was allowed to proceed for 3 hr at 4 C, beads were then washed 3 times in
SNAP buffer and nucleosomes resuspended in NuPAGE protein loading buffer. The experiment was performed in duplicate.
Immunoblotting
Cell fractions and extracts were quantified by BCA (Pierce). Samples were boiled in Laemmli buffer or NuPAGE buffer and equal
amounts (10 mg) of cell fractions (equal volumes for immunoprecipitates) were loaded for each treatment. When blotting for Pol II
phospho-forms, cells were lysed in TOPEX+ buffer (50 mM Tris-HCl pH7.5. 300 mM NaCl, 0.5% Triton X-100, 1% SDS, 1 mM
DTT, 1x Complete protease inhibitor (Roche), 5 mM NaF, 0.2 mM Na3VO4,10 mM b-glycerophosphate, and 33 U/ml benzonase
(EMD-Novagen). Proteins were resolved by SDS-PAGE with size markers (ThermoFisher) and transferred to nitrocellulose membranes (GE Healthcare). Proteins were detected with primary antibodies to DNMT3A (Abcam ab2850), TRRAP (Abcam ab73546),
SET (Abcam ab181990), LMNA (Abcam ab26300), HMGN1 (Bethyl Laboratories A302-263), UTF1 (Abcam ab24273), CDK9 (Abcam
ab6544), beta-Tubulin (Abcam ab6064), RUVBL2 (Abcam ab36569), SF3A3 (Bethyl Laboratories A302-506A), ZFP57 (Abcam
ab45341), FUS (Novus Biologicals 100-565), LARP7 (Novus biologicals A303-723A), ILF3 (Abcam ab92355), CyclinT1 (Abcam
ab184703), UBTF (Santa Cruz sc-13125), KAP1/TRIM28 (Abcam ab3831), SUZ12 (Santa Cruz sc-46264), LEO1 (Bethyl Laboratories
A300-174A), HNRNPU (Abcam ab10297), EHMT1 (Abcam ab41969), STAG1 (Abcam ab4457), STAG2 (Abcam 4463), SMARCC1
(Abcam ab172638), BRD4 (Santa Cruz sc-48772), INO80 (ProteinTech 18810-1-AP), CHD1 (Cell Signaling D8C2), CHD4 (Abcam
ab70369), CHD8 (Bethyl A301-224A), P300 (Santa Cruz sc-585), KDM2A/JHDM1A (Bethyl A301-475A), MPP8 (Santa Cruz sc398598), Pol II S2P (Abcam ab5095), Pol II S5P (Millipore 05-623), total Pol II (Santa Cruz sc-899), Beta-actin (Cell Signaling
4967S), histone H3 (Abcam ab1791) and gH2A.X (Ser139) (clone JBW301) (Sigma 05-636-I). Proteins were visualized using Amersham ECL western blotting detection reagent (GE) and detected using an ImageQuantLAS 4000 imager and ImageQuantTL (GE).
Contrast and brightness were altered in a linear fashion equally across the whole image. Proteins exhibit changes in chromatin association or nucleosome binding that were not validated by immunoblotting are indicated in Tables S1, S3, and S5.
7SK knockdown
ESC were trypsinized and nucleofected with 1 nmole of scrambled or 7SK ASO (Flynn et al., 2016) per 2x106 ESC using the Amaxa
4D-Nucleofector X Unit (Lonza VPH-1001) with the Amaxa 4D-Nucleofector Protocol for Mouse ESC. After nucleofection, cells were
re-plated and cultured for 8 hr. RNA was purified using TRIsure (Bioline BIO-38033) according to the manufacturer’s instructions and
reverse transcribed with SuperScript III (ThermoFisher) using random hexamer primers. Enrichment of cDNAs compared to input
control was measured by qPCR (Applied Biosystems) using QuantiTect SYBR Green PCR kit (QIAGEN 204143) with primers for
7SK 50 -AGAACGTAGGGTAGTCAAGC 30 and 50 - AGAAAGGCAGACTGCCACAT 30 and Actb 50 -TCTTTGCAGCTCCTTCGTTG30 and 50 -ACGATGGAGGGGAATACAGC-30 . The experiment was repeated 7 times.
CLIP
CLIP was performed as described (Huppertz et al., 2014) with the following differences: cells were irradiated with 0.2 J/cm2 of 254 nm
UV light in a Stratalinker 2400 (Stratagene). 5x106 cells were used per IP and were lysed in 1 mL of lysis buffer with Complete protease
inhibitor (Roche). Lysates were passed through a 27 G needle, 4 U/ml of DNase Turbo (Ambion AM2238) and RNase I (Ambion
AM2294, range between 1-20 U/ml) added, and incubated in a thermomixer at 37 C and 1100 rpm for 3 minutes. 5 mL of a-RUVBLl2
(Abcam ab36569), 5 mg a-UBTF (Santa Cruz sc-13125), 5 mg a-INO80 (ProteinTech 18810-1-AP), a-CHD4 (Abcam ab70369),
a-SMARCC1 (Abcam ab172638), a-EHMT1 (Abcam ab41969), a-CDK9 (Santa Cruz sc-484), a-LARP7 (Bethyl A303-723A),
a-SMARCA5/SNF2H (Abcam ab3749), a-INTS11 (Bethyl A301-274A), a-CCNT1 (Abcam ab238940), a-CDK9 (Santa Cruz sc-484),
a-LARP7 Bethyl A303-723A) or non-specific IgG (Abcam ab46540) antibody was used per experiment and bound to 50 ml of prewashed Dynabeads protein G beads (Invitrogen 10003D) for 1 hr at RT. Antibody-bound beads were then incubated with lysate
for 5 hr at 4 C. Beads were washed 3 times with 900 ml of high-salt buffer (supplemented with 1 M urea) and twice with 900 ml of
wash buffer. After transfer, the membrane was washed twice with 1x PBS, exposed overnight to a phosphoimager screen (Fuji),
and visualized with an Amersham Typhoon Trio image scanner. Protein and RNA bands were quantified with ImageJ. CLIP experiments were performed in duplicate.
iCLIP
iCLIP was performed as described (Huppertz et al., 2014) with variations from Beltran et al. (2016). Cells were irradiated with 0.2 J/
cm2 of 254 nm UV light in a Stratalinker 2400 (Stratagene), 6-10x107 cells were used per IP. Cells were lysed in 1 mL of lysis buffer,
lysates passed through a 27 G needle and sonicated for 3x 10 s pulses with a Diagenode Picoruptor. 200 U/ml of DNase Turbo (Ambion), and 4 U/ml of RNase I (Ambion) were added and lysates incubated in a thermomixer at 37 C and 1100 rpm for 3 mins. Lysates
were cleared by centrifugation and Proteus clarification spin columns, according to the manufacturer’s instructions. 5 mg of antibody
e6 Molecular Cell 81, 1–16.e1–e10, July 15, 2021
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
was used for each CLIP (CDK9 Santa Cruz sc-484; LARP7 Bethyl A303-723A). After SDS-PAGE and transfer to membrane, crosslinked RNPs between 80 and 110 kDa (CyclinT1) or 70 to 100 kDa (LARP7) were isolated. iCLIP for the CyclinT1 input sample was
performed as described (Beltran et al., 2016), extracting RNPs between 80-110 kDa. RNA was purified and after reverse transcription, cDNA was fractionated by running samples on a precast 6% TBE-urea gel at 180 V for 40 mins and cDNA bands running between 120-180 nt (high), 85-120 nt (medium) and 70-85 nt (low) isolated. One ml of each fraction was pooled to optimize the number of
cycles in the PCR, determined by the minimum number of cycles that produced detectable amplicon in gels stained with SYBR Green
I (Invitrogen S7585). Once the optimal number of optimal cycles was established, the library PCR was performed separately for each
fraction, checked by gel electrophoresis and pooled in equal proportions. Library concentration was determined using the KAPA Universal Library Quantification kit (Roche KK4824), according to the manufacturer’s instructions and library concentration was corrected by multiplication by 0.38 to account for insert size. Single-end 50-bp reads were generated on a HiSeq 2500.
Co-immunoprecipitation from chromatin
ESC were treated with 10 mM triptolide or an equivalent volume of DMSO for 6 hours, trypsinized and the chromatin fraction purified
as described (Beltran et al., 2016; Zoabi et al., 2014). Chromatin was resuspended in 50 mM Tris (pH 8), 1 mM EDTA and 20 U/ml of
DNase Turbo (Ambion AM2238) for 30 min at RT, followed by the addition of 0.5% sodium deoxycholate and sonication for 10 3 30 s
pulses with a Diagenode Picoruptor. Once the chromatin fraction was completely dissolved, IP buffer (20 mM Tris-HCl, 0.5% NP-40,
150 mM NaCl, 1.5 mM MgCl2, 10 mM KCl, 10% Glycerol, 0.5 mM EDTA, pH 7.9, 1 mM DTT, Complete protease inhibitor and 1 U/ml
RNaseOUT (Invitrogen 1077019)) was added up to 1 mL and centrifuged for 5 min at 13,000 rpm to pellet any insoluble material. 50 ml
of the sample was saved as input and the remaining sample pre-cleared with Protein G Dynabeads at 4 C for 1 hr. The beads were
removed, each sample divided into two, and incubated with 2.5 mg of anti-CCNT1 (Abcam ab238940) or non-specific IgG for 16
hours. Samples were then incubated with Protein G Dynabeads at 4 C for 2 hours. Beads were washed 5 times with IP buffer
and centrifuged for 5 min at 1,000 rpm at 4 C to remove any remaining supernatant. Laemmli buffer was added to half the beads
and inputs and processed for immunoblotting and the other halves were resuspended in TRIsure for RNA purification. RNA was
treated with DNase Turbo and reverse-transcribed with the ImProm-II Reverse Transcription System (Promega A3800) using random
hexamer primers. Enrichment of 7SK versus 5S rRNA was measured by qPCR (Applied Biosystems) using QuantiTect SYBR Green
PCR kit (QIAGEN) with primers for 7SK 50 -AGAACGTAGGGTAGTCAAGC-30 and 50 -AGAAAGGCAGACTGCCACAT-30 and 5S rRNA
50 -AAGCCTACAGCACCCGGTAT-30 and 50 -GATCTCGGAAGCTAAGCAGG-30 . The experiment was repeated 3 times.
RNA-seq
ESC were mock or RNaseA treated or treated with 10 mM triptolide or flavopiridol for 0, 1, 3 or 9 hours. For whole cell extract RNA,
cells were resuspended in TRIsure. For chromatin-associated RNA, cells were fractionated as described (Werner and Ruthenburg,
2015) with minor modifications. Cells were re-suspended in 1 mL of buffer A (10 mM HEPES (pH 7.9), 10 mM KCl, 1.5 mM MgCl2,
0.34 M sucrose, 10% glycerol, 1 mM DTT with Complete protease inhibitor), Triton X-100 (0.1%) added, and the cells were incubated
for 5 mins on ice. Nuclei were collected by low-speed centrifugation (4 min, 1,300 g, 4 C) and washed twice in buffer A. The pellet was
resuspended in 250 ml NUN buffer (20 mM HEPES pH 7.6, 300 mM NaCl, 1M Urea, 1% NP-40, 7.5 mM MgCl2, 1 mM DTT, with protease inhibitor) and incubated for 10 mins on ice, then centrifuged (1,400 g, 4 min, 4 C). The resulting pellet was washed twice with
buffer A and an equal volume of TRI Reagent (Sigma T3934) was added to the chromatin pellet. Before RNA extraction, we spiked-in
5% of Drosophila cells resuspended in TRIsure into the whole cell extract RNA samples and 1% into the chromatin-associated RNA
samples. RNA was purified following the manufacturers protocol and treated with DNase Turbo. Libraries were generated from WCE
RNA by polyA selection and from chromatin-associated RNA library by rRNA depletion and sequenced by GENEWIZ.
Cell cycle, caspase activation, cell death, gH2A.X
ESC were treated with triptolide or flavopiridol as above, or with 10 nM SN-38 (Sigma H0165) for 24 hr. Cells were then trypsinized and
resuspended in media. Cell viability was measured using eF780 (Invitrogen 65-0865-14) in triplicate. Caspase-3 and 7 activation
was measured in duplicate using the Vybrant FAM Caspase-3 and 7 assay kit (Invitrogen V35118) following the manufacturer’s instructions with a BD LSR Fortessa X-20. For cell cycle analysis, cells were fixed with 70% ethanol, washed with PBS and incubated
with 100 mg/ml RNaseA (Sigma) and 25 mg/ml propidium iodide from the sVybrant FAM Caspase kit for 10 mins at RT. Cells were then
analyzed by flow cytometry in triplicate and the data averaged. For gH2A.X analysis, cells were treated with triptolide or flavopiridol as
above, or with 10 mM doxorubicin (Sigma D1515), and whole cell extract purified. The experiment was performed 3 times.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical tests used and n are stated upon first use in the Results text and in the figure legends.
Mass-spectrometry data analysis
SILAC
Raw data were analyzed in MaxQuant v1.6.0.13 (Cox and Mann, 2008) and searched against a UniProt Mus musculus protein database downloaded 14/06/2012 using default settings. A SILAC quantification method (multiplicity 2) using light amino acid labels (K0
Molecular Cell 81, 1–16.e1–e10, July 15, 2021 e7
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
and R0) and heavy labels (K8 and R10) was selected. Carbamidomethylation of cysteines was set as fixed modification, and oxidation
of methionines and acetylation at protein N-termini were set as variable modifications. Enzyme specificity was set to trypsin with
maximally 2 missed cleavages allowed. MaxQuant generated a reverse database for decoy searching and an internal protein
contaminant database was also searched containing sequences including trypsin and keratins. A 1% FDR at the protein and peptide
level was selected.
LFQ
Raw data were analyzed in MaxQuant v1.5.2.8 and searched against the same UniProt database. Label-free quantification was
selected with a match time window of 0.7 min, an alignment time window of 20 min to quantify the proteins with the ‘match between
runs’ feature selected. Other settings were the same as for SILAC.
LC-MS/MS data post-processing and analysis
The ‘proteinGroups.txt’ quantification files were used for statistical data analysis and the Pol II inhibition, RNase-treated chromatin
and RNase-treated nucleosome affinity purification experiments processed separately. Proteins marked as Potential contaminant,
Only identified by site, Reverse by MaxQuant and proteins with less than two peptides identified were excluded. The remaining proteins were classified into nuclear and non-nuclear proteins based on subcellular location information in UniProt (UniProt Consortium,
2019) as of 2018-12-18. Subcellular locations Nucleus, Nucleus speckle, Chromosome, Nucleus matrix, Nucleus envelope, Nucleus
inner membrane, Nucleus membrane, Nucleus outer membrane were treated as nuclear. Proteins with no localization information
were assumed to be nuclear. Non-nuclear proteins were discarded. Intensities (either SILAC-labeled or LFQ) of the remaining
proteins were normalized using TMM (Robinson and Oshlack, 2010). For SILAC experiments, log2 protein intensities were
converted into log2(H/L) ratios which were compared between forward and reverse experiments. Outlier proteins that did not
show typical anticorrelation between forward and reverse H/L ratio in SILAC experiments were detected and removed by estimating
the direction of first and second principal components of pooled ratios of significantly enriched proteins in all experiments (forward
log2 ratio > 1.25, reverse < 1.25 or vice-versa) and discarding all proteins 2.5-standard deviations away from the median in the
second principal direction. This procedure was been performed twice, adjusting the PCA estimates once more after removing outlier
proteins. Intensities of remaining proteins were re-normalized again using TMM. The ratio outlier filtering step was skipped in LFQ
dataset.
Normalized intensities of remaining proteins were analyzed using Limma (Kammers et al., 2015; Ritchie et al., 2015). Three and
nine-hour Pol II inhibition datasets were analyzed separately, as were RNase-treated chromatin and nucleosome affinity purification
experiments. SILAC experiments were modeled based on the log2 intensities of proteins, assuming additive treatment (inhibitor
versus DMSO or RNase versus Mock) effect, additive mix (SILAC experiment batch) bias, and additive isotope (H/L labeling) bias.
The change of intensity after washout of flavopiridol (relative to intensity after 3 hr flavopiridol treatment) was modeled as an additional parameter in three-hour inhibition model. The change of intensity after addition of tRNA (as compared to RNase treatment
without tRNA) was modeled similarly in SILAC nucleosome purification experiments. The label-free chromatin RNase treatment dataset was modeled assuming additive treatment effect (RNase versus Mock) and paired experiment batch effects. Limma models were
fitted with trend parameter set. Statistical testing was performed on treatment and washout/tRNA terms. P values were adjusted by
Benjamini/Hochberg method, significance was assumed at FDR of 0.05. Comparisons between the different experiments were performed by matching the outputs by UniProt protein IDs, discarding rows that map ambiguously. To allow direct comparison to the Pol
II inhibition data, only proteins with UniProt protein IDs that were also present in the RNA pol II inhibition dataset were visualized in the
RNaseA treatment volcano plots and FDR values were calculated based on the population of proteins that were also detected in the
RNA Pol II inhibition experiment.
We identified proteins that were significantly enriched or depleted in the chromatin fraction upon treatment with both flavopiridol
and triptolide at 9 hr (FDR < 0.05). To measure the effect of flavopiridol washout, we identified all proteins significantly enriched or
depleted on chromatin after 3 hours incubation (FDR < 0.05) that were also detected in the washout experiment (n = 523). We then
calculated the Pearson correlation between log2(FP 3hr/DMSO 3hr and log2(washout/FP3hr) and its significance (corr.test in R,
which applies a t test). We also identified proteins significantly enriched or depleted in the chromatin fraction after RNaseA treatment
(FDR < 0.05) and proteins with significantly increased or decreased binding to nucleosomes after RNA degradation (FDR < 0.05). We
took the set of proteins significantly enriched or depleted in the chromatin fraction upon treatment with both flavopiridol and triptolide
at 9 hr and calculated the average change in chromatin binding between the two treatments. We then calculated the correlation between these values and the change in chromatin binding caused by RNaseA treatment. The significance of correlations between datasets was estimated using corr.test in R. The significance of overlaps between sets of proteins depleted or enriched on chromatin
after Pol II inhibition and RNaseA treatment were compared using the hypergeometric test in R using the set of proteins detected in
both treatments as the population.
Gene names were reannotated using the Mouse Genome Informatics (MGI) database and used to perform enrichment analysis
against the GO (release 2020-01-01), Reactome (2020-2-7), KEGG (2020-02-03) and WP (20200110) databases using the hypergeometric test in g:Profiler2 v1.2 (Raudvere et al., 2019). Mouse proteins annotated with the terms RNA processing (GO:0006396) or
Chromatin organization (GO:0006325) were downloaded from AmiGO 2 (http://amigo.geneontology.org/amigo) and used to identify
proteins with these functions in the volcano plots. Mouse gene names were also mapped to human gene names using Ensembl BioMart (http://useast.ensembl.org/biomart/martview/0e2a64a75123489044c7f7866711cb8d). Mouse gene names that did not match
e8 Molecular Cell 81, 1–16.e1–e10, July 15, 2021
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
any human gene names using BioMart were checked using HGNC multi-symbol checker (https://www.genenames.org/tools/multisymbol-checker/) and then mapped to their human gene names. Protein complexes with significant enrichment of subunits in the set
of recruited or depleted proteins were identified from CORUM 3.0 (03.09.2018) (Giurgiu et al., 2019) using the hypergeometric test in
g:profiler2 v1.2. Subunits missing from CORUM were manually added to the cytoscape figures and a hypergeometric test repeated to
ensure the complexes remained significant. Additional complexes or functionally related groups not annotated in CORUM were also
added if significant (these were DNMTs, EHMTs, HUSH, NoRC, P-TEFb, SEC and SAFB factors in Figure 1C and PRC1.6 and NSL in
Figure 3C). Complexes were depicted using Cytoscape v3.5 (Shannon et al., 2003). Interactions between proteins in these complexes was taken from STRING v11 (Szklarczyk et al., 2019) using experiments as the active interaction source.
iCLIP data analysis
iCLIP data were processed using iCount (https://github.com/tomazc/iCount) as described (Beltran et al., 2019). The unique molecular identifiers (UMIs) were registered and experimental barcodes removed before mapping the sequences to mm9 using Bowtie
version 0.12.7 (command line: -v 2 -m 1 -a–best–strata) in iCount. Reads indicative of PCR duplicates (reads mapping to the
same position with the same UMI) and reads aligning to multiple positions in the genome were removed. Data from independent replicate samples were then added together (P-TEFb n = 3; LARP7 n = 2, Input n = 1, P-TEFb in pla-B-treated cells n = 1, P-TEFb in
DMSO-treated cells n = 1). When mapping crosslinks to genes, crosslinks overlapping a RepeatMasker feature or ncRNAs under
200 nt in length or annotated as a snoRNA were removed. Crosslink sites were assigned to the nearest splice site junction by iCount
(Ensembl59 annotation). First exon-intron, mid exon-intron, intron- mid exon and last intron-exon junctions were defined as those
uniquely annotated with these designations by Ensembl59. The number of crosslink sites at each position were normalized by the
total number of exons or introns at that position and by the total number of crosslink sites in the dataset multiplied by 109. The
data points were smoothened over a 12-nt sliding window using the smth.Gaussian function from the smoother package in R
with smoother.gaussianwindow.alpha = 2.3 and plotted with the ggplot2 package in R. We used MISO (Katz et al., 2010) to identify
included exons (posterior mean value > 0.90) and excluded exons (posterior mean value < 0.10) from previously published mESC
mRNA-seq data (Beltran et al., 2016). Exon-intron junctions that were also annotated in Ensembl 59 were retained and P-TEFb
and input crosslinks over the exon-intron boundaries were normalized, smoothened and plotted as above. When plotting RNA crosslinking at individual genes, high-confidence clusters of crosslink sites were identified using the low FDR function in iCount (FDR <
0.05), with a 50 nt flank (König et al., 2010).
For comparison of P-TEFb RNA crosslinking at single-exon versus multi-exon genes, exon number was identified from the Ensembl 59 annotation. The number of P-TEFb and input RNA crosslinks per gene were normalized by the total number of reads mapping to all the genes and multiplied by a factor of 1 million. For genes with crosslinks in both samples, the log2 ratios (P-TEFb/input)
were plotted and a t test performed.
For mapping crosslinks to 7SK and snRNAs, non-transcribed 7SK pseudogenes were masked in the mm9 genome sequence and
reads aligned using bowtie2 version 2.1.0 (command line parameters:–very-sensitive–no-unal) (Langmead and Salzberg, 2012).
Reads aligning to multiple positions in the genome were removed, but for this analysis, reads mapping to the same position with
the same UMI were retained due to the risk of high abundance target RNAs saturating the number of possible UMIs (45).
RNA-seq analysis
RNA-Seq data were aligned to concatenated mouse-Drosophila genome (mm9 and BDGP5.25 assembly) using STAR (version
2.7.3a) (Dobin et al., 2013). Uniquely mapped reads were extracted from the aligned bam files, which were then split into Mouse
and Drosophila. The number of reads mapping to the Drosophila genome were used to calculate a scaling factor that was then
used to scale the Mouse bigwig files generated using deepTools (version 3.0.2) (Ramı́rez et al., 2016). Exonic and intronic coordinates
were extracted from Ensembl 67 annotation and featureCounts (Liao et al., 2014) in R used to count the number of reads in exons or
introns for each Mouse gene. The number of reads mapping to a gene in Drosophila was counted by featureCounts using a gtf file
(version 5.25). DESeq2 (Love et al., 2014) was used to calculate the size-factors for the Drosophila reads and these were then used to
normalize the read counts mapping to the Mouse genome. A pseudo-count of 1 was added to the data and log2 ratios calculated
relative to t = 0 (for Pol II inhibition) or mock (for RNaseA). Gene biotype information was downloaded for Ensembl 67 using BioMart
(Smedley et al., 2009). Genes with a non-coding biotype were assigned to lincRNA biotype after manual curation. Cumulative frequency distribution plots were generated from log2 ratios using ggplot2 (Wickham, 2016). Metagene plots were generated using
the computeMatrix and plotProfile functions in deepTools.
Comparison to RNA binding studies
Proteins detected to bind RNA in previously published studies were downloaded from (Caudron-Herger et al., 2019) and the data
compared to our data using human protein names. Proteins that increase on chromatin upon both 9hrs TRP and FP treatment
(FDR < 0.05), proteins that decrease on chromatin upon both 9hrs TRP and FP treatment (FDR < 0.05) and proteins remaining constant on chromatin upon both 9hrs TRP and FP treatment (FDR > 0.05) were identified and the proportion of proteins in each of these
sets identified to bind RNA in each study was quantified. The significance of the proportion of proteins that increase and decrease on
chromatin identified as RNA binding proteins was estimated relative the proportion of non-changing proteins identified as RNA binding proteins using the Binomial test and the p values adjusted for multiple hypothesis testing to reflect the 12 studies assessed.
Molecular Cell 81, 1–16.e1–e10, July 15, 2021 e9
Please cite this article in press as: Skalska et al., Nascent RNA antagonizes the interaction of a set of regulatory proteins with chromatin, Molecular Cell
(2021), https://doi.org/10.1016/j.molcel.2021.05.026
ll
Article
CLIP and immunoblotting
P-TEFb (n = 7) and LARP7 (n = 2) RNA crosslinking was quantified in cells treated with 7SK ASO relative to RNA crosslinking in cells
treated with scrambled ASO and normalized to change in CyclinT1 or LARP7 protein amount. The mean and SD of these values were
then plotted and the significance of the change in RNA crosslinking (7SK/scrambled) estimated using a 1-sided Welch’s unequal variance t test.
CyclinT1, CDK9, LARP7 and SMARCC1 chromatin binding was quantified 3 or 6 hr after treatment with triptolide relative to before
treatment in the same cell line in triplicate and the mean and SD plotted. The significance of the difference between WT and KO cells
at the same time point was estimated using a 1-sided Student’s t test.
e10 Molecular Cell 81, 1–16.e1–e10, July 15, 2021